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With advances in, and cost reduction of next generation sequencing technologies, assessing
the presence of microbes in host niches in healthy and diseased states has become a more
feasible task. However, these studies are often only limited to bacterial characterization,
ignoring other important community members such as fungi, viruses, and protists. The research
presented here begins to fill this gap by creating a roadmap for fungal community analysis. With
fungal outbreaks on the rise, it is essential that the fungal kingdom is included in future
microbiome analyses to gain a more comprehensive understanding of commensal species, how
they maintain a healthy niche, and their impact on acquired diseases.

One particularly at-risk group of immune compromised patients are those undergoing
chemotherapy. Approximately 40% of such patients develop a debilitating side effect known as
oral mucositis, which is complicated by severe pain, inability to eat and speak, and severe
bacterial and fungal infections. The research in this dissertation focuses on three aims
necessary for answering the question of how fungal genera are implicated in oral mucositis.
First, we present a roadmap from sample processing to data analysis, describing challenges
and solutions for characterizing fungal communities in any human-health related metagenomics
study. Second, we address the healthy fungal mycobiome of saliva, providing evidence for new
and existing members of the oral niche, while assessing the temporal variability in community
composition in a healthy state. Third, we characterize the oral genera during chemotherapy in a
longitudinal study of cancer patients, and document their changes during the progression and
development of oral mucositis. Revealing and meeting the challenges associated with fungal
metagenomic analysis by means of initial hand curation will pave way for development of new,

much needed library preparation and bioinformatics tools. But above all, pinpointing community
trends for susceptible subjects will ultimately provide unprecedented insight for implementation
of prophylactic measures in cancer patients.
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Chapter 1. Introduction
1.1

Overview

The ultimate purpose of this study is to provide a basis for understanding how fungi play a role
in the development and progression of oral mucositis or other comorbidities arising as a result of
chemotherapy. With the mouth being the main entryway into the body, characterizing the fungi
here is especially important for understanding the relationship between fungal profiles and their
implications in human health and disease.

1.2

Fungi as opportunistic pathogens

Fungi are arguably the most underappreciated and least understood organisms that inhabit
planet Earth. They persist in nearly every ecological niche and are crucial in sustaining all other
life forms by supplying essential nutrients through the decomposition of organic matter. With
species estimates ranging from 1.5 to 5.1 million, fungi are among the most environmentally
abundant and diverse eukaryotes1,2.
Detrimental fungal infections of eukaryotes have occurred throughout history, causing
ecosystem and economic turmoil with incidents such as the Irish potato famine of the twentieth
century and the recent decline in over 40% of Central American amphibian species 3. On a much
longer time scale, fungi have been postulated to shape the deep evolutionary history of life.
Although naturally increased body temperatures tend to prevent fungal colonization in
endothermic animals, ectothermic animals must rely on increasing internal temperatures by
adjusting their external surroundings. Prehistoric climate changes toward colder temperatures
and decreased sunlight may have led to unhindered fungal infection and extinction of the
dinosaurs, and ultimately to the rise of mammals4. Fungal adaptation to rising global
temperatures will require new host defenses and give opportunity for bouts of mammalian
extirpation4.

1

Fungal threat to human survival is exacerbated by the marked increase of immunocompromised
individuals over the last several decades due to the ability of opportunistic fungi to turn from
commensal to pathogenic5. Investigations of fungal outbreaks at the Centers for Disease
Control and Prevention have increased from 1-2 per year in 1990 to 3-6 per year in 20156.Most
commonly, these outbreaks are caused by contamination in medications or environmental
transmission. People with lowered defense systems are the most susceptible to such infections.
Immunosuppression, whether induced or acquired, has led to changes in fungi from noninvasive commensals to dangerous pathogens. Emerging infectious diseases caused by
invasive species of Fusarium, Scedosporium, Trichoderma, Paecilomyces, Dactylaria,
Wangiella, Cladophialophora, Rhizopus, Cunninghamella, and Mucor have joined the ranks of
those caused by the more well-known human pathogens of Candida, Aspergillus, and
Cryptococcus species7.
Several recent outbreaks have been due to medicinal contamination. A recent review of 21st
century fungal outbreaks by the CDC in 2012 of Fusarium sp. and Bipolaris sp. were caused by
contamination of medications used for visualizing vitreous tissues during virectomies (Brilliant
Blue G and triamcinolone). As a result, these products caused 47 patients to acquire
endophthalmitis, with the majority losing vision. Another 2012 outbreak, now the deadliest to
date, was due to methylprednisolone acetate, used to treat joint swelling, arthritis, and severe
allergic reactions. These injections affected 752 patients of the potentially 14,000 that were
exposed across 23 states. Of those affected, there were onsets of meningitis, arachnoiditis, or
spinal abscesses, and a total of 64 deaths6.
Environmental exposure has also caused unexpected transmission of pathogenic fungi. In 2008
and 2009 the CDC also reported that a Rhizopus species was isolated from hospital linens in
New Orleans. Of the five children infected, all of them died from cutaneous mucormycosis. A
species of Apophysomyces was also identified in a patient injured by debris in a tornado. Whole
2

genome sequencing revealed that three isolates were the cause of the necrotizing cutaneous
mucormycoses in 13 patients, giving further evidence to the cause being environmental in
nature rather than as acquired as a single source infector6.
In nature, fungi exhibit a vast potential for mutualistic relationships due to their ability to adapt to
new surroundings. However, other organisms must evolve to protect themselves from fungal
infection, as fungi do not rely solely on survival of their hosts3. Fungi thrive in soil and on
decaying matter. It is in these environments that they have evolved a great deal of their
virulence factors against amoebae, bacteria, and other threatening microorganisms8. The
notable human pathogen, Cryptococcus neoformans, provides a well-understood illustration of
the linkages between adaptation, virulence, and unintentional consequences for vulnerable
hosts. For example, nonvirulent strains of Cryptococcus neoformans are easily eliminated due
to ingestion by other environmental occupants such as amoebae and nematodes. But with
pathogenicity intact, the fungus is able to replicate inside of its captor and induce cytotoxicity
due to its protective capsule. The capsule is made mostly of glucuronoxylomannan (GXM),
which increases in size in the presence of phospholipids released by cells in the surrounding
environment, granting protection from reactive oxygen species9. The capsule also provides a
mechanism against dehydration for environments with low humidity. Coincidentally, the
evolution of the capsule for protection in its natural environment gave C. neoformans the ability
to cause disease in unintentional hosts, which use macrophages to employ defensive strategies
similar to C. neoformans’s natural predators. C. neoformans infections have been found in many
mammalian species including domestic pets, dolphins, and sheep10.
In the 1970s, C. neoformans infection incidences were approximately 1 in a million per year in
the U.S. They have risen markedly since then because of the spread of HIV, and account for
13-44% of HIV patient deaths from sub-Saharan Africa, implicating C. neoformans as an
opportunistic pathogen11. Immunocompetent hosts may also be infected with C. neoformans,
3

especially in tropical climates, but those that are immunocompromised have a much higher rate
of infection. Infections are generally caused by inhalation of Cryptococcus spores and lead to
three diseases including pulmonary cryptococcosis, cryptococcal meningoencephalitis, and
cutaneous cryptococcosis. Cryptococcal meningoencephalitis, the most deadly cryptococcal
disease, causes 10-30% of HIV related deaths worldwide. Spores remaining undetected in the
lungs and are able to disseminate and target the central nervous system if gone untreated or
the host’s immune system becomes compromised. As the infection spreads to the brain,
symptoms include headache, fever, vision or hearing loss, cognitive impairment, and
hydrocephalus11.

1.3

Fungi in oral mucositis

Understanding how fungi become pathogenic is especially important in populations that undergo
induced immune deficiencies. Many cancer patients receiving radiation and chemotherapy
treatments experience the debilitating side effect of oral mucositis. Oral mucositis (OM) is the
manifestation of lesions in the mouth due to damage of mucosal epithelial cells 12. The
breakdown of this important immunological barrier oftentimes leads to severe pain, poor
nutrition, and microbial infections12. The onset and progression of OM cannot currently be
predicted, but it is clear that oral microbiota play a large role in sustaining oral health13.
OM is commonly experienced by all groups of patients undergoing chemo- and radiation
therapies. Nearly 100% of patients irradiated for head and neck cancers and over 50% of
patients receiving chemotherapy for breast cancer have been diagnosed with this
complication12. OM occurs in five complex stages after administration of chemotherapeutics,
generally over the course of two weeks: 1) initiation of direct damage to mucosa due to
therapeutics; 2) primary damage response by the immune system;3) amplification of the
immune response; 4) ulceration; and 5) spontaneous healing14.
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Of those afflicted with OM, approximately 39% suffer from oral fungal infections during
treatment, with Candida spp. as prime pathogens15. It is commonly assumed that all forms of
candidiasis associated with oral mucositis are caused by C. albicans, but frequently, physicians
do not perform tests for species level identification. Commonly, patients are encouraged to
manage mucositis with increased oral hygiene (about once every four hours), and are often
prescribed rinses for washing away food and bacteria, for pain, or for offering a protective
coating over the mucosal lining. One such product, MuGard®, defended 57% of head and neck
cancer patients, from experiencing ulcerative oral mucositis and showed mean weight-loss to be
less than half of the control group16. MuGard® contains benzyl alcohol and benzalkonium
chloride, which are known to be bacteriostatic agents, but also contains Carbomer
Homopolymer A, providing a gel layer that protects from any outside aggressors. This suggests
that environmental factors coupled with microbial communities influence nearly half of patients
that develop OM. While these treatments are available, there are still a great deal of patients
that continue to suffer from OM.

1.4

Fungi in next-generation genomics

Fungi have traditionally been classified using morphological and culture-based techniques.
Although it is still the gold standard in the diagnosis of some infections, this approach is limited
by the inability to culture many fungi, lengthy incubation times, and the microscopic similarities
that many species share17. Providing a suitable treatment in the early stages of fungal infection
is paramount in patient recovery and survival17.
With the introduction of DNA sequence technologies, fungi can now be identified with higher
sensitivity using molecular markers. In 2011, a multinational and multilaboratory initiative was
undertaken to determine a DNA barcode region for accurate identification of fungal species18.
The largest subunit of RNA Polymerase II (RPB1), and three regions of the nuclear rDNA
cistron: 28S large subunit (LSU), 18S small subunit (SSU), and internal transcribed spacers
5

(ITS) were evaluated as promising candidates based largely on their representation in reference
sequence databases. Of these, the ITS region demonstrated both a high rate of success in PCR
amplification and sequencing as well as sufficient inter- and intra-species variability. This led to
the proposal of ITS as the universal barcode for identification of fungi18. The general presence
of the ITS regions is conserved to maintain spacing in the fungal rDNA operon, but their specific
nucleotide sequences are independent of ribosomal function. The flanking, sequence-conserved
18S, 5.8S, and 28S subunits are appropriate targets for primer design, allowing for universal
amplification of ITS in clinical and environmental samples. However, mixtures of
microorganisms are commonly encountered in real-world samples, thus requiring timeconsuming cloning steps to accomplish traditional methods of dideoxy sequencing.
The next-generation sequencing era has eliminated lengthy culturing and cloning steps and
allowed for the high-throughout, massively parallel acquisition of ITS sequences. The ability to
sequence millions of ITS DNA fragments in a single experiment has revolutionized the
exploration of fungal communities and microbial interactions. Many organizations, such as the
Human Microbiome Project, have been established to catalog the diversity in microbiomes
across different regions of the human body in states of health and disease, but their main focus
has been on bacteria. Indeed, many sophisticated pipelines have been developed to evaluate
the complexity and biodiversity of bacterial communities. Although bacteria are essential for
sustaining equilibrium of the niches they inhabit, they do not act alone, and are also impacted by
the fungi that surround them. Pioneering next-gen studies on fungi have revealed that the
complexity of human-associated fungal communities, or “mycobiomes,” may even increase with
the complexity of bacterial microbiomes19. Nevertheless, tools developed for prokaryotes are not
easily translated to analysis of fungal ITS because they rely on global alignments of small
subunits. While the variability in ITS permits identification of species, it confounds alignment
across fungal genera20.

6

The entire ITS region, spanning approximately 450-700 bp for most fungi and including the 5.8S
rRNA gene was recommended as the universal fungal barcode, but its length complicates nextgeneration sequencing experiments and analysis21. The addition of sequencing adaptors and
conserved flanking regions for primer binding can extend these lengths by several hundred
base pairs. Many next-gen platforms sequence approximately 200 bp without the need for
bidirectional sequencing and assembly. With less than 1% of the estimated 5.1 million fungi
represented in ITS sequence databases21, relying on sequence assembly to accurately assign
and quantitatively portray fungal communities is non-ideal. Roche’s 454 pyrosequencing with
Titanium XLR70 chemistry offers mode read lengths of 450 bp, while the most recent Titanium
XL+ reagents extend mode lengths to 700 bp. At the time this study began, 454 was the only
method capable of obtaining long reads (>400 bp) without the need for sequence assembly.
ITS1 and ITS2, sequenced independently, are sufficient for fungal identification21 and reduce
sequences to 454 manageable lengths. There is no consensus between groups on which ITS
region should be used for fungal identification, with amplification biases apparent in both
instances and preferential representation of non-fungal sequences using only ITS221,22.
At the time this project was started, there was only one other publication attempting to perform
metagenomic analysis for oral samples23. Ghannoum and colleagues sequenced ITS1
amplicons from 20 healthy subjects and reported the core components as those representing
1% relative abundance within each subject at ≥ 20% frequency. The most frequent species
were Candida, Cladosporium, Saccharomycetales, Aspergillus, Fusarium, and Cryptococcus,
four of which are well known human pathogens. The average number of reads was 1,702 per
sample, obtained with 454 sequencing. In some samples, as many as 60% of the sequenced
fungi were considered to be “non-culturable”. Other biocompartments have recently been
assessed for fungi including gut and sputum24,19, also using the ITS1 region as a target for
sequencing.
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Though sequencing-based approaches of fungal identification have made characterizing
communities a possibility, they are not without limitations. Further complications arise due to
ambiguous taxonomic classification. Fungal species undergo morphological changes between
their sexual and asexual states, originally leading scientists to assign multiple names to a single
species without knowledge that their DNA sequences were identical. In April 2011, the
Amsterdam Declaration on Fungal Nomenclature was enacted to transition mycologists toward
a nomenclature system that allows only one name for one fungus25. This document declares
that regardless of sexual state, a fungus should be considered by its first given name, with
exceptions to those that are more widely recognized by younger synonyms. Not all situations
are resolved with this document and it will not be until the 2017 Shenzhen Congress that other
exceptions are addressed26. The work presented herein attempts to take these matters into
consideration by employing a holistic approach to making fungal representation relevant to the
biomedical community. It is the first to quantify the effects of collapsing synonymous genera into
a single category.

1.5

Specific aims

This study provides a roadmap for analyzing fungal communities by first characterizing oral
fungi in health, and then temporally after administration of oncologic treatments. The findings
here will offer possibilities for development of preventative OM strategies and shed light on
profiles susceptible to infection in all cases of immunosuppression. The project has three
specific aims:

1. To develop a method for obtaining fungal ITS1 sequences from human saliva and
to empirically curate taxonomic results. This aim has been accomplished by
optimizing methods for breaking fungal cells, validating taxonomic legitimacy using e-
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value thresholds, addressing dual and synonymous nomenclature of fungi, and
evaluating non-genera classifications for re-assignment to the genus level.

2.

To refine the concept of the core mycobiome in the healthy mouth. This aim has
been accomplished by characterizing the core oral fungi in healthy saliva from 6 donors
using a 454 deep sequencing approach. Genera at a frequency of at least half of the
participants were considered to be core oral members. Validation of empirically
determined parameters from Aim 1 were also employed here and 24 additional healthy
subjects were mapped to the core and used to determine minimum sequencing depths
necessary for capturing 95% of sample richness. Genus level mycoprofile frequencies
were determined and variation in two week differences were explored.

3. To characterize the fungal communities in patients undergoing treatment for
cancer. This aim has been accomplished by 454 sequencing and pipeline application
from aim 1 of 21 healthy subjects assessed for baseline time points two weeks apart and
17 cancer chemotherapy patients at 4 time points of Day 0, Day 2, Day 9, and Day 14,
with minimum sequencing requirements met for every collection. Comparisons were
made to determine differences in mycoprofile abundances between healthy and cancer
cohorts.

9

Chapter 2. Methods and standard operating procedures
2.1

Introduction

This study employs metagenomic techniques to explore the fungal composition of the human
salivary microbiome. While many of these approaches are used in similar metagenomic studies,
our pipeline has been optimized to yield amplifiable, fungal genomic DNA for sequencing
Internal Transcribed Spacer 1, while reducing pre-sequencing artifacts. The subsequent
computational pipeline has proven to reduce non-informative post-sequencing artifacts and to
return legitimate identifications for fungal genera. Using controls to evaluate the breadth of
identifiable genera showed the need to take precaution in accepting automated taxonomic
assignments and in considering the complications of fungal nomenclature when reporting
community proportions. The methods in this thesis are presented as detailed standard operating
procedures as performed by Dupuy, et al.27 and are applied to all clinical samples in a parallel
fashion.
Precautions were taken to keep samples free of contamination for each protocol by using
personal protective equipment (gloves, lab coat at extraction step) and sterile filter tips for
pipetting. Optimal standard operating procedures were developed by comparing different
extraction methods and PCR protocols (methods and results not shown) for a series of control
subjects, reagent blanks, and C. albicans samples.

2.2

Ethics statement

Development of methods for this research project required healthy human volunteers and was
performed according to a protocol (number X13-030) approved by the Institutional Review
Board (IRB) of the University of Connecticut. The Institutional Review Board has determined
that this study meets the criteria for Waiver of Informed Consent stated in 45 CFR
46.116(d).Conduct of research with respect to cohorts 1-3 was performed according to a
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protocol (number UCHC11-037S-2) approved by the IRB of the University of Connecticut and
UConn Health Center (UCHC). The UCHC was assigned as the IRB of record and agreed to
inform the UConn Storrs IRB of all instances of unanticipated problems, should they occur.

2.3

Library preparation and sequencing workflow

2.3.1 Sample collection
Saliva Collection for Healthy Pilot Samples (Samples 50-52, 54-57)- location UConn Storrs:
Volunteers were instructed to refrain from eating and drinking non-water beverages for at least
one hour before donating saliva samples. While medical records and health statuses were not
formally measured, all six subjects were in their twenties and reported to be systemically
healthy, non-smokers, and had no known oral conditions. Subjects expectorated about 3 mL of
saliva into 50 mL Falcon tubes. Saliva was resuspended gently with a pipette and duplicate 1.5
mL aliquots were centrifuged at 3,300×g for 10 minutes. Supernatants were carefully removed
to leave 200–300 µL and a pellet in each tube; in the case of large stringy pellets, as much
supernatant as possible was removed without interfering with visible pellet material. Pellets from
duplicate tubes were combined, re-pelleted, and supernatants removed to leave 200–300 µL
that was extracted immediately or stored at −80°C.
Saliva Collection for Oral Mucositis Study (Arms 1-3)- location UCHC:
Subjects were restricted from oral hygiene on the date of collection, must have gone at least two
days without antibiotics and antimicrobial rinses, must have refrained from smoking and gum
chewing for at least four hours prior, and must have refrained from eating at least one hour prior
to collection. Unstimulated saliva was collected for a total of five minutes in a 15 mL falcon tube
placed in ice using a sterile plastic funnel. Tube content was aliquotted into as many 1.5 mL
tubes as required and was centrifuged for 10 minutes at 3,300×g. Supernatants were removed
without disturbing pellets or “jelly” like glycoprotein clumps. Pellets were frozen at −80°C. Pellets
were thawed and resuspended in 200 µL TE buffer (20 mM Tris pH 7.0, 2mM EDTA). For 16S
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bacterial amplification, 50 µL was removed. The remaining sample volume was re-frozen and
delivered to UConn Storrs on dry ice for fungal amplification.

2.3.2 Fungal extraction using modified MP Biomedical FastDNA™ Spin Kit
Note: During this protocol it is important to open tubes only in the biosafety cabinet and to keep
any exposed skin covered when handling. If gloves become contaminated at any point, replace
2nd glove layer or use 70% EtOH to clean. It is not recommended to exceed 8 sample
extractions at a time. An extraction negative should also be included as a control totaling 9
parallel extraction processes.
1. With gloved hands, for each sample, use lysing matrix B and pour out B beads until total
mass of tube + beads = 1.8 g. Add 1 gram of yttria stabilized zirconium beads to create B&Y
custom lysing matrix. (Total weight = 2.8 g)
2. Place lysing matrix tubes on their sides in the small UV instrument for 15 minutes, ensuring
that beads are distributed evenly across side of tubes.
3. When tubes are prepared, put on a fresh pair of gloves and lab coat.
4. Tape sleeves of lab coat to first pair of gloves so that skin remains covered.
5. Clean biosafety cabinet and pipettes with 10% bleach, followed by 70% ethanol.
6. Turn UV on in the hood for 15 minutes with pipettes inside.
7. Place a tube rack inside incubator and pre-heat to 55 °C.
8. After UV cycle completes, turn on biosafety cabinet, and put on a second pair of gloves over
first pair of gloves.
9. Add 800 μL of CLS-Y solution to the lysing matrix.
10. Short spin sample tubes for 15 seconds.
11. Resuspend sample pellet and add entire sample volume to the lysing matrix tube.
12. Homogenize samples in FastPrep® 24 at speed 5 for 30 seconds.
Note 1: Ensure that lysing matrix tubes are labeled on their sides, not tops, as FP®24
will rub off labels on caps of tubes.
Note 2: Tighten top of FP24 until 3 clicks are heard.
13. Store samples on ice during 5 minute cool down of FP24.
14. Repeat steps 12-13 2x, omitting ice incubation step after 3rd homogenization.
15. Spin samples for 10 minutes at 14,000 RCF.
16. Carefully transfer as much supernatant as possible to a 2 mL tube, ensuring that no beads
or pelleted cellular material is removed in the process.
17. Vortex Binding Matrix until it is resuspended.
18. Add 700 μL of well-mixed Binding Matrix to 2 mL tube with supernatant. Re-vortex stock
Binding Matrix if it begins to settle before distributed to all samples.
19. Invert 2 mL tubes ~20 times by hand to mix.
20. Rotate in Labquake® for 5 minutes.
21. Pipette up and down 2-3 times before transferring 700 μL to spin filter in catch tube.
Note: Make sure to collect any sample that remains in the lid of the 2 mL tube.
22. Spin at 14,000 RCF for 1 minute.
23. Discard supernatant from catch tube and replace spin filter.
Note: Make sure to check supernatant for any Binding Matrix beads that may have leaked
through filter. If spin filter is “leaky”:
i. Resuspend liquid and beads in catch tube and return it to spin filter.
ii. Resuspend entire contents of spin filter.
iii. Transfer bead/liquid mixture into a new spin filter.
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iv. Repeat steps 21-22.
24. Transfer remaining resuspended sample (650 μL max) to spin filter.
25. Spin at 14,000 RCF for 1 minute.
26. Discard supernatant from catch tube and replace spin filter.
27. Repeat steps 24-26 if any sample is left.
28. Thoroughly resuspend the pellet with 500 μL SEWS-M to wash (gently, so as to not shear
DNA).
29. Spin for 1 minute at 14,000 RCF.
30. Discard supernatant in catch tube and replace spin filter.
31. Repeat steps 28-30.
32. Spin for 2 minutes at 14,000 RCF without any new addition of solutions.
33. Transfer spin filter to a clean catch tube.
34. Thoroughly resuspend the pellet with 100 μL DES to elute DNA.
35. Place tubes into pre-heated 55 °C incubator for 5 minutes (make sure lids are closed).
36. Spin for 1 minute at 14,000 RCF.
37. Discard spin filters and transfer eluate from catch tube to a clean 1.5 mL tube.
Note: 1.5 mL tubes should be labelled with the sample identification number, the date
extracted, and “B&Y Ex”.
38. Make sure no crystals form in DNA after ~10 minutes.
Note: If crystals have formed, spin tube at max speed for 10 minutes and transfer
supernatant to a clean 1.5 mL tube.
39. Store eluted DNA in 4 °C (or -20 °C long-term).
40. Clean up space as described in steps 6-7 and turn off biosafety cabinet.

2.3.3 Determination of DNA concentration via the NanoDrop 2000
1. Clean biosafety cabinet and pipettes inside it with 10% bleach, followed by 70% ethanol.
2. Turn UV on in the hood for 15 minutes.
3. Check the sample tubes for crystal formation. If crystals have formed:
a. Spin samples for 10 minutes at 14,000 RCF.
b. Remove supernatant and place into a new 1.5 mL tube.
4. If no crystals have formed, vortex samples briefly (1-2 seconds).
5. Short spin the sample tubes to bring gDNA to bottom.
6. Remove 2 μL of extracted gDNA and place into a labelled PCR tube for each sample.
7. Add 2 μL of DES to a PCR tube for blanking the instrument.
8. Clean biosafety cabinet as in steps 1-2 and turn off.
9. Open NanoDrop 2000 program.
10. Create new file or open previous file.
11. Clean the NanoDrop plate and arm with a Kimwipe® pre-wetted with dH2O and then dry.
12. Add 1 μL of DES to the NanoDrop plate.
13. Lower the arm of NanoDrop onto the plate and hit the blank button on the program.
Note: Before measuring, ensure that no bubble has formed on top of the plate. If
a bubble has formed, use the arm to try and pop the bubble on the plate.
14. Clean the NanoDrop plate and arm with a dry Kimwipe®.
15. Add 1 μL of the gDNA sample onto the NanoDrop plate.
16. Name run to match your sample.
17. Hit the measure button on the program.
18. Repeat steps 13-16 for all samples.
19. Clean the NanoDrop plate and arm with a Kimwipe®.
20. Print results.
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2.3.4 PCR protocol for universal fungal ITS1 amplification
The fusion primers used in this protocol were designed for use with the 454 GS FLX Titanium,
for sequencing with Lib-A DNA Capture Beads “B” in the forward direction (from 18S to 5.8S).
From 5’ to 3’, fusion primer design entails a 454 adaptor sequence (A/B), a Multiplex Identifier
(MID), and the template specific sequence. Standard 454 adaptor sequences were:
Adaptor A 5’-CGTATCGCCTCCCTCGCGCCATCAG-3’ and
Adaptor B 5’-CTATGCGCCTTGCCAGCCCGCTCAG-3’.The template specific sequences were:
ITS1 Forward Primer (ITS1F) 5’-CTTGGTCATTTAGAGGAAGTAA-3’28 and ITS1 Reverse
Primer- (ITS2) 5’-GCTGCGTTCTTCATCGATGC-3’29. MID sequences were selected from 454’s
Technical Bulletin No. 004-2009 and are listed in table 2.1. The entire primer formats specific to
the “B” sequencing direction were: forward primer 5’-454 Lib-A Adaptor B, MID, ITS1F-3’ and
reverse primer 5’-454 Lib-A Adaptor A, MID, ITS2-3’.
ID

MID Sequence- 5’3’

MID1

ACGAGTGCGT

MID2

ACGCTCGACA

MID3

AGACGCACTC

MID4

AGCACTGTAG

MID5

ATCAGACACG

MID6

ATATCGCGAG

MID7

CGTGTCTCTA

MID8

CTCGCGTGTC

MID10

TCTCTATGCG

MID11

TGATACGTCT

Table 2.1: MID sequences used for
multiplexing of all samples

14

1. Determine the amount of gDNA needed for each PCR reaction:
DNA volume = 125 ng / NanoDrop concentration (in ng/µL)
Hyclone PCR water volume = 25 µL reaction volume – 9.625 µL total PCR
components volume (includes 5 µL buffer, 1 µL each primer, 2.5 µL dNTPs,
0.125 µL polymerase)
2. Determine MID assignment for each sample, spreading samples evenly between MIDs
1-8, 10, 11, and with controls assigned to MID 1.
3. Cover PCR hood area in new bench coat.
4. Wipe down pipettes with 10% bleach, followed by 70% ethanol.
5. Expose hood, pipettes, a PCR rack, PCR water, and OneTaq® Buffer to UV for 15
minutes.
6. Turn on hood and label triplicate PCR tubes for each sample and each extraction
negative to be amplified, and a single tube for both a positive control and a reagent
blank.
7. Thaw MID-tagged Lib-A ITS1 primer aliquots, dNTPs, and positive Candida albicans
control DNA. Briefly vortex and centrifuge these tubes alongside samples to be
amplified.
8. To each PCR tube, add the calculated volume of PCR water. (15.375 µL for reagent
blank and 14.875 µL for positive control).
9. Add 5 µL of 5X OneTaq® Buffer (final concentration: 1X).
10. Add 2.5 µL 2.0 mM (pre-mixed) each dNTP (final concentration: 0.2 mM).
11. Add 1.0 µL 5 µM (Lib-A ITS1-F + adaptor B + MID-tagged) primer (final concentration:
0.2 µM).
12. Add 1.0 µL 5 µM (Lib-A ITS2 + adaptor A + MID-tagged) primer (final concentration: 0.2
µM).
13. Add the calculated volume of template gDNA for each sample. (0.5 µL of 2 ng/µL
Candida albicans gDNA).
14. Add 0.125 µL 5 U/µL New England BioLabs OneTaq® Hotstart Polymerase (final
concentration: 0.025 U/µL).
15. Briefly vortex and spin each PCR tube.
16. Run pre-heated PCR with the following conditions:
a. 94 °C for 30 seconds (1x)
b. 94 °C for 30 seconds, 50 °C for 60 seconds, 68 °C for 60 seconds (35x)
c. 68 °C for 5 minutes (1x)
d. 10 °C hold
17. Clean PCR hood and pipettes as in step 4. Turn off hood and begin UV for 15 minutes.
18. Store tubes up to 3 days at 4 °C.
1% Agarose and TBE Gel Procedure
Part 1: Preparation of Sample
1.
2.
3.
4.

Add 1.25 μL of 5X Cresol Red into new labelled PCR tubes.
Briefly vortex and spin down all PCR products to be run on gel.
Add 5 μL of each PCR product into the appropriate tube containing Cresol Red.
Briefly vortex and spin down samples.
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Part 2: Preparation of a 1% agarose, 1X Tris-borate-EDTA gel with ethidium bromide
Gels reagents (TBE, agarose, ethidium bromide) can be proportionally scaled up to create a
larger gel for running more samples.
1. Tare a quarter sheet of weighing paper.
2. Weigh 1.0 g of agarose and add to a pre-cleaned 500 mL flask.
3. Add 100 mL of 1X TBE.
Note: Rinse the neck of the flask with the TBE solution while adding to ensure
that any agarose powder trapped on the neck is brought down.
4. Swirl gently, but thoroughly, in both directions.
5. Place the flask into a microwave and heat until solution until the solution begins to
bubble/foam.
Note: Room lights can be turned off to aid in seeing bubbles.
6. Using a hot pad, remove the flask and swirl gently one way for 5 seconds, and then swirl
gently the other way for 5 seconds.
7. Repeat steps 6-8 2X until bubbles are big (not foamy).
8. Check the solution to make sure it is completely clear of any remaining agarose powder.
9. Let solution cool for 20 minutes.
10. Carefully add 1 µL of ethidium bromide to the flask and dispose of tip in ethidium
bromide waste.
Note: Ethidium bromide is a DNA intercalating agent and may be carcinogenic.
11. Gently, but thoroughly, swirl the solution to ensure the ethidium bromide is dispersed
evenly.
12. Pour the agarose solution into a 100 mL tray that has been tightly secured to a level gel
mold with the appropriate number of gels combs placed for sample loading and ladders.
13. Quickly rinse the 100 mL flask a few times with de-ionized water to clean and leave to
dry upside down.
14. Check to see if bubbles are in the gel. If bubbles are present:
a. Take a P10 pipette tip and turn it upside down so the large opening is facing the
gel.
b. Insert the pipette tip until the bubble in the gel is sucked up by the tip.
c. Remove and discard the pipette tip in ethidium bromide waste.
15. Let the gel solidify for approximately 1 hour.
Part 3: Running samples on the gel
1. Carefully loosen the handle on the gel mold and remove the gel plate.
2. Fill a BioRad Sub-Cell® GT (that is attached to a Bio-Rad PowerPac™ Basic ¾ full with
1X TBE.
3. Place gel plate on the center of the rack.
4. Fill with 1X TBE until gel wells are completely covered. Remove lane combs carefully.
5. For each row of lanes that is present, pipette 1.5 μL of prepared 1 Kb+ ladder into the 1st
lane (i.e. 2 row of lanes=1st lane in each row has Kb+ ladder).
6. Pipette the entire PCR product and Cresol Red mixture into a lane, making sure not to
poke the bottom of the gel.
7. Repeat step 6 for all samples.
8. Place BioRad SubCell® GT lid onto the SubCell GT, matching colors.
9. Power on the BioRad PowerPac™ Basic.
10. Set voltage to 100V.
11. Set mA to 400.
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12. Set time for 60 minutes.
13. Begin by hitting the start (running man) button.
14. Once on, ensure that bubbles begin to form at the black end of the SubCell® GT.
15. Let gel run for 60 minutes, periodically checking to ensure that the DNA/ladder from one
lane does not run into the second row of lanes.
16. Turn off BioRad PowerPac™ Basic.
17. Remove the gel, holding your fingers on the bottom of the gel to ensure that the gel
does not slide off the gel plate and pour off excess buffer. Dry the bottom of the plate
with Kimwipes®.
18. Open the tray of the BioRad Gel Doc™ and place gel with tray.
19. Close the tray and turn on the Trans UV light.
20. Log onto computer using Bo’s username and password= P@ssW0rd.
21. Open BioRad Quantity One program.
22. Hit GelDoc EQ button, live focus, and auto expose.
23. Adjust the exposure manually if necessary.
24. Freeze and save the gel image.
25. Click the file button, export to tiff, click export gain, and click save.
26. Click the print button, print under “Mitsubishi P95”.
27. Exit program and turn off the Trans UV light.
28. Remove gel and place in designated waste bucket.
29. Rinse off gel plate with water.
30. Clean BioRad Gel Doc™ with 70% ethanol.
31. Evaluate for presence of bands (~300 bp for positive control) for each sample and for
contamination in reagent blank and extraction negatives.
32. For replicate samples that performed equivalently, combine into a new 1.5 mL tube.
33. Store samples at 4 °C.

2.3.5 AMPure® XP size selection of fungal ITS1 amplicons
1. Vortex Agencourt® AMPure® XP reagent bottle to resuspend magnetic particles that
may have settled.
2. Briefly vortex and spin samples. Measure the volume of each sample being tested via
pipette.
3. Add 1.8 µL Agencourt® AMPure® XP reagent beads for each 1 µL PCR product for the
first cleanup.
Note: After the first cleanup and Pippin Prep procedure, the ratio is reduced to
1.5 : 1 Agencourt® AMPure® XP reagent beads to sample volume or 1.3 : 1 and
1.0 : 1 for further cleanups.
4. Mix thoroughly by pipetting 10x. The color of the mixture should be homogenous after
mixing.
5. Incubate samples for 10 minutes at room temperature to bind sample DNA to the
magnetic beads.
6. Place the sample tubes on a magnetic particle concentrator (MPC) for 5 minutes to
separate the beads from the solution. Ensure that the solution has cleared before
proceeding.
Note: The hinges of the tube should be directly next to the magnetic part of the
stand.
7. With the tubes still on the MPC, aspirate the solution from the tubes and discard the
solution.
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Note 1: Do not disturb the beads. If necessary, leave a few µl of supernatant
rather than disturbing the beads.
Note 2: If the beads are disturbed, mix the supernatant thoroughly with the
beads, and allow them to sit on the MPC for another five minutes before trying
again.
8. Remove tubes from the MPC and add 200 μL of 70% ethanol.
9. Mix solution well via pipetting.
10. Incubate for 30 seconds at room temperature and place tubes back onto the MPC.
11. After the solution has cleared, aspirate the solution from the tube and discard.
12. Repeat steps 8-11 a second time.
13. Quick spin all tubes to bring down any remaining ethanol from the sample tubes.
14. Place the tubes back onto the MPC and allow the beads to travel up to the side of the
tube.
15. Remove any ethanol from the tube and discard.
Note: Be sure to remove all ethanol, as it is a known PCR inhibitor. A P10 may
be necessary to remove the small volume of ethanol in this step.
16. Open the tops of the tubes and allow the beads to dry for 5 minutes at room
temperature.
Note: Watch the beads during this step. If any of the beads begin to crack,
immediately proceed to the next step. Over drying beads significantly decreases
elution efficiency; however, leftover ethanol may inhibit PCR.
17. Remove tubes from the MPC and add 30 μL Qiagen elution buffer (EB) to each tube.
18. Mix by pipetting 10x.
19. Replace tubes back onto the MPC and allow the samples to incubate for 5 minutes at
room temperature.
20. SLOWLY, and CAREFULLY, transfer as much of the 30 μL eluate to a new 1.5 mL tube.
Note 1: Do not suck up any of the beads. Use a P200 pipette to remove most of
the solution. Then tilt the Magnetic Stand 96 at an angle and remove as much of
the solution as possible using a P10 pipette.
Note 2: If the beads are disturbed in the solution, resuspend the solution with the
beads, and allow the sample to pellet to the MPC before trying again.
21. Store samples at 4 °C.

2.3.6 Sage Science Pippin Prep™ size selection
1. Briefly vortex and spin each sample, Loading Solution, and DNA Marker B. Measure the
volume of each 1.8 AMPure® size selected sample via pipette.
2. Bring volume of each sample up to 30 μL with Qiagen Elution Buffer (EB).
3. Slowly pipette 10 μL of Loading Solution to each sample tube.
4. Briefly vortex and spin down all sample tubes.
5. Turn on Sage Science Pippin Prep™ and monitor, and allow the PX00476 software to
automatically turn on.
6. Remove the 2% agarose Pippin Prep™ gel cassette from its foil bag and inspect the
buffer levels in all of the lanes. If the levels are not even, add Electrophoresis buffer until
level.
7. Inspect the gel cassette for delamination in the lanes.
Note: If a lane has delamination, that lane cannot be loaded with ladder. Sample
solutions may be loaded onto this lane if necessary.
8. Remove any bubbles from the elution chamber (dark blue center) by tilting the cassette
elution side up until the bubble moves away from the area.
9. Open the Pippin Prep™ and place the gel cassette onto the optical nest.
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10. Pull off the adhesive tape from the gel cassette.
11. Remove buffer from the elution module.
12. Add 40 μL of fresh Electrophoresis Buffer to each elution module.
Note: Make sure you don’t have any bubbles. Pop the bubbles with the pipette
tip, or remove the buffer and try inserting the buffer again.
13. Seal elution wells with adhesive tape strips, ensuring that the tape does not cover the
optical module.
14. Fill sample wells with Electrophoresis Buffer until solution is “convex” in each well.
15. Close the Pippin Prep™ and perform the Continuity Test by clicking “TEST” in the main
tab.
16. If a lane fails the elution criteria, use that lane for ladder. If it passes, it can be used for
sample. If a lane fails the separation criteria, neither sample nor ladder should be used
in that well.
17. On the Pippin Prep™ software go to the Protocol editor and click new.
18. Set as “2% marker B No Overflow Detection”.
19. Considering steps 7 and 16 choose a lane for reference (marker B). Set the rest of the
samples lanes as “range”.
20. Set base pair start to 160 bp.
21. Set base pair end to 1000 bp.
22. Fill in the sample ID template with the sample ID or ladder.
23. Click Save-as, and name the file.
24. Open the Pippin Prep™ and refill sample wells with Electrophoresis Buffer if they are no
longer convex.
25. Remove 40 μL of Electrophoresis Buffer from sample wells.
26. Add 40 μL of marker B or sample into the appropriate sample wells, ensuring that the
pipette tip does not touch the bottom of the well or the sides of the well.
27. Add Electrophoresis Buffer in a drop wise manner until the sample well is convex,
making sure to never touch the sample in each lane to avoid contamination.
28. Close the Pippin Prep™ lid and hit start.
29. Once the test has finished (2.5 hours), remove the ~40-60 μL of sample volume from
each elution module and place it into a new labelled 1.5 mL tube.
30. Shut down program and turn off monitor.
31. Pour liquid from gel cassette into ethidium bromide liquid waste and dispose of the
cassette in ethidium bromide solid waste.
32. Store samples at 4 °C.

2.3.7 Bioanalyzer dimer removal verification and AMPure® XP size selections
Follow the standard operating procedure for AMPure® XP Size Selection of Fungal ITS1
Amplicons procedure following the note for 1.5 µL beads: 1 µL PCR product at step 3. Then,
dilute the amplicon appropriately to the range of detection for the Bioanalyzer in elution
buffer. Dilutions can be estimated using the agarose gel result to get within 15-200 pg/µL.
Prepare the Bioanalyzer DNA High Sensitivity Gel-Dye Mix
If solution is already prepared skip this section
1. Allow the High Sensitivity DNA dye concentrate (blue cap) and High Sensitivity DNA gel
matrix (red cap) to equilibrate to room temperature for 30 minutes in the dark before use.
2. Add 15 μL of High Sensitivity DNA dye concentrate (blue cap) to High Sensitivity DNA
gel matrix (red cap).
3. Vortex solution well and spin down briefly.
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4. Centrifuge solution of at 2240 RCF +/- 20% for 10 minutes.
5. Wrap tube with aluminum foil to protect the solution from light.
Note: Once the Gel-Dye Mix is prepared, it is good for 6 weeks.
Clean the Agilent 2100 Bioanalyzer:
Note: This process should only be performed after all runs are completed for the day. Washing
electrodes before or between runs introduces the risk of improper drying and consequently,
poor results.
1.
2.
3.
4.
5.
6.

Add 350 μL of deionized water to the “Washing-DNA Only” Bioanalyzer chip.
Dab the top of the plate with a Kimwipe® to remove any excess DI water.
Place the chip onto the Agilent 2100 Bioanalyzer and close the lid.
Leave the chip in the instrument for 60 seconds, and then remove the chip.
Pipette water out from the chip.
Repeat steps 1-5 three times.

Running a sample on the Agilent 2100 Bioanalyzer
1.
2.
3.
4.
5.
6.

Open 2100 ExpertBioA program.
Select DE13804730.
Select Assays.
Select ds DNA.
Select High Sensitivity assay.
Put a new High Sensitivity DNA chip on the chip priming station.
Note: The next steps need to be done within 5 minutes.
7. Pipette 9 μL of gel-dye mix into the well marked with circled “G”.
Note: The solution is very viscous. To pipette the solution, push the pipette
aspirator button down past the second stop. Remove the solution. Then pipette
the solution into the well, pushing only to the first stop.
8. Align plunger at 1 mL position. Push syringe down until it is held by the metal clip.
9. Let sit for exactly 60 seconds.
10. Release the plunger and wait for 5 seconds. Pull the plunger back into the 1 mL position.
11. Open the chip priming station and add 9 μL of gel-dye mix to the remaining 3 wells in the
far right hand column, excluding the previously filled well.
12. Remove 70 μL of marker (green cap) and place into a new 1.5 mL microcentrifuge tube.
13. Pipette 5 μL of marker into all sample wells (even if unused) and the ladder well.
14. Add 1 μL of High Sensitivity DNA ladder (yellow cap) into the well marked with a
pictogram of a ladder.
15. Pipette 1 μL of sample into each of the remaining 11 sample wells.
Note: If a well is not being used for sample, add 1 μL of marker.
16. In the 2100 ExpertBioA program, label the wells with their corresponding sample ID.
17. Place the Bioanalyzer chip onto the IKA MS3 vortex and push in the chip to start
vortexing for 1 minute at 2400 rpm.
18. After the vortex is finished, remove the Bioanalyzer chip and place it into the Agilent
2100 Bioanalyzer.
19. Hit start on Expert BioA program.
a. Note: Be cautious around the Agilent 2100 Bioanalyzer when it is running.
Vibrations around the machine will adversely affect results.
20. When the chip is finished running, remove and discard the chip.
21. Perform Bioanalyzer cleaning procedure as outlined.
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Bioanalyzer 2100 Expert Analysis
1. Navigate to appropriate run to be analyzed.
2. Click on the “Global” tab on the right hand side of the screen, then use the dropdown
menu to select “Advanced”. Use this option.
3. Under ladder setpoints, check the box to perform Baseline Correction.
4. Under sample setpoints, check the box to perform Baseline Correction.
5. Click “Apply to All” at the bottom of the Global settings.
6. Double click on single sample to view it individually and select the “Region Table” tab.
7. Ensure that the baseline is flat and the upper marker is a single complete peak, (which
returns to baseline and is higher than the lower marker). Ensure that the amplicon is not
perturbed by artifacts. If electropherogram fails to meet these requirements retry sample
in another Bioanalyzer run.
8. Click on the “range” tab at the bottom of the screen for each individual sample and
record the concentration in pg/µL for the 200 bp-1 kb automated smear analysis. (If
necessary, adjust the smear to include all DNA).
Note: If primer artifact peaks appear at 160 bp or less, additional AMPure XP
washes are necessary (1.3 : 1 or 1.0 : 1 volume ratios). Samples that require
additional cleanups will need to be repeated on another Bioanalyzer run.

2.3.8 Dilution of samples to 1.00×108 molecules/μL and pooling
1. Use concentration derived from the Bioanalyzer chip to determine the volume of DNA
and volume of Qiagen elution buffer (EB) necessary for diluting the sample down to
1.00×108 molecules/μL.
Bioanalyzer concentration of sample (molecules/µL) =
Bioanalyzer concentration (pg/µL) * 6.022 x 1023 (Avogadro’s number molecules/mole)
6.56 x 1014 (Avg ng of bp/mole) * 326 bp (estimated ITS1 amplicon length based on C. albicans)
Bioanalyzer concentration of sample (molecules/µL) x sample volume (µL) =
1.00×108 molecules/μL x 20* µL
*Choose an appropriate volume in order to make the calculated volume
reasonable for pipetting.
2.
3.
4.
5.
6.
7.
8.
9.

Vortex and spin samples briefly.
To a new 1.5 mL tube, add the exact volumes of DNA and EB to each tube.
Vortex and spin down all of the tubes.
Determine which samples to combine into one pool, while taking care not to use two of
the same MIDs in one pool.
Add 5μL of each sample to its corresponding pool tube.
Vortex and quick spin the pool tubes.
Run the pooled samples on a High Sensitivity Bioanalyzer chip to ensure that the final
concentration of the sample is 1.00×108 molecules/μL.
Store samples at 4 °C.
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2.3.9 emPCR and sequencing
1. Dilute 1x108 molecule/µL pools to 4x106 molecules/µL in a new tube with EB.
2. Follow 454 emPCR Amplification Method Manual – Lib-A MV or SV using Capture beads
“B” and medium or small volume emulsion oil for 4 or 8 region gaskets, respectively.
Protocol found at:
http://454.com/downloads/my454/documentation/gs-flx/methodmanuals/GSFLX_GSFLXPlus_emPCRAmplificationMethodManual_LibA_SV_Jun2013.pdf
3. Follow 454 Sequencing Method Manual
Protocol found at:
http://454.com/downloads/my454/documentation/gs-flx/method-manuals/GS-FLXTitanium-Sequencing-Method-Manual-%28Nov2010%29.pdf

2.4

Fungal ITS1 data analysis

Required downloads: QIIME, bioperl, DeconSeq, Virtual Box

2.4.1 Transfer raw data and create sff files
1. Move R Signal processing folder into the dated sequencing folder that was transferred to
admin rig. Delete duplicate files from folder.
2. Create a folder for each region under signalprocessing/sff
3. Use terminal to parse raw region sff files by MID to generate sff files for each sample. sfffile -s
<regionname>01.sff
4. Drag newly generated sff files into appropriate pool folder.
5. Repeat for other regions.
6. Generate a text file containing raw sequence outputs for each MID.
7. Copy entire dated sequencing run folder to DROBO or other external storage device.

2.4.2 Transfer data for analysis
1. On data analysis computer, open WinSCP and log on to CAGT computer using ssh.
2. Copy .fna (fasta) files from external storage to CAGT.
3. Open virtual box and start up QIIME machine.
4. Click on the terminal and ssh into CAGT.
5. cd into folder you just created with fna files inside.

2.4.3 Run dimer removal program:
1. perl ../DimerRemovalUseThisOne/08302013dimer_remove.pl 1.TCA.454reads.fna
../DimerRemovalUseThisOne/08302013dimer.fn [enter]
2. Repeat for remaining regions and grep to get sequence counts in output files. Example: grep
">" 1.TCA.454reads.fna_good.fn | wc -l [enter]
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2.4.4 Run DeconSeq program
1. type “screen” then:
deconseq -f /home/amanda/[name of folder containing fasta file]/1.TCA.454Reads.fna_good.fn c 90 -i 94 -dbs
arch,bact,bacthmp,dr,hs_alt_celera,hs_alt_CRA,hs_alt_HuRef,hs_alt_KoRef,hsref,hs_unique,m
m,senterica,vir
2. CTRL + A + D to detach
3. type screen again and run command on each "good" fasta file.
4. type more <run#>_a[tab] for each of the four run #s and note which region belongs to which
run#.
5. type screen -list to note the screen numbers for each run: To resume a screen type screen -r
<screen#>.pts-<#>.cagtflx. When process is finished type: exit (to erase screen).

2.4.5 Run QIIME split_libraries.py command
1. Create a tab separated mapping file for each region with this format:
#SampleID BarcodeSequence LinkerPrimerSequence ReversePrimer Treatment SequencingDate
#mapping file for the QIIME analysis package.
2-019-1 ACGAGTGCGT CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-001-1 ACGCTCGACA CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-001-2 AGACGCACTC CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-001-3 AGCACTGTAG CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-001-4 ATCAGACACG CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-008-1 ATATCGCGAG CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-005-2 CGTGTCTCTA CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-014-3 CTCGCGTGTC CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy
2-020-2 TGATACGTCT CTTGGTCATTTAGAGGAAGTAA GCTGCGTTCTTCATCGATGC Healthy

Description
20140203
20140203
20140203
20140203
20140203
20140203
20140203
20140203
20140203

MID1
MID2
MID3
MID4
MID5
MID6
MID7
MID8
MID11

2. Save file as MappingFile<PoolName#>.txt
3. Use WinSCP to copy clean and contam files to Analysis computer. Rename them so they
reflect Poolname.
3. Logout of ssh and Split libraries in terminal of analysis computer QIIME:
qiime@qiime-VirtualBox:~/Desktop/Shared_Folder/OMFPools1-4$ split_libraries.py -m
MappingOMFPool1.txt -f [filtered pool 1 file name]_clean.fa -l 100 -L 10000 -t -a 1 -H 10 -M 2 -e
2 -b 10 -z truncate_only --reverse_primer_mismatches 6
4. Make new folder for each Pool and transfer seqs.fna, log, and histogram files into appropriate
folder so that next command doesn't overwrite these files.
5. Repeat for other pools and move files to folders as they complete.
6. Rename sequence files to contain pool name.

2.4.6 Remove short sequences with Galaxy
1. Go to windows explorer and navigate to: ftp://usegalaxy.org
2. Login with galaxy id and credentials.
3. Copy QIIME pass fna files to galaxy ftp.
4. In internet browser go to https://usegalaxy.org and login.
5. Click Get Data> Upload File and check boxes in FTP section once files are finished
uploading. Click Execute.
6. Once files turn green click FASTA manipulation > Filter sequences by length. Select file,
Minimal length = 100, maximum length = 0 [execute]
7. Click pencil to rename output files to <Poolname>100plus
8. Click Name of file > Disk image to save.
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9. Remove brackets ([ ]) from saved files.

2.4.7 Submit to FMP for taxonomic identification
1. Open FMPShare Folder on analysis computer.
2. Copy and paste 100plus files into FMPShare.
3. Navigate to FMP Portal: https://biotech.inbre.alaska.edu/portal/ and log in with credentials.
4. Once files finish uploading click Applications > Microbial Pipeline > Search Fungal ITS.
5. Type email, name job, and Select from Secure File Share. Browse for file. Choose
curated_its in dropdown and keep Blast in search dropdown. Click Run.
6. Save blastall.summary file.

2.4.8 Removal of sequences by e-value filter
1.
2.
3.
4.
5.

Use excel to open blastall.summary file.
Find and replace “e-“ with “1E-“ using case sensitivity.
Sort e-value column from high to low.
Paste data for “good” e-values ≤ 1x10-42 in a new file.
Search for each sample name and create a new tab delimited text file for the good e-values,
leaving the first two rows without data.

2.4.9 Run taxa counting program
1. Open QIIME virtual box and transfer .txt files for each sample using transferring procedure in
2.4.2.
2. Run perl gi_sgp.pl [samplefilename].txt for each file to generate a list of genera and their
counts.

2.4.10 Standard operating procedure for combining genera
Finally, genera were collapsed by hand curation using biblioinformatic guidelines suggested by
Hawksworth30. In addition to the recommended citations in Google, Google Scholar, and
Bibliography of Systemic Mycology (BSM), NIH PubMed citations were added in deference to
the biomedical orientation of this research. Google searches were qualified with “fungus” when
the genus names mapped to objects other than fungi (as an example, valsa refers to a waltz as
well as a fungal genus). A holistic approach was used for conjoining genera. Synonyms were
identified using Uniprot, BSM, and original literature. Because sexual and asexual pairs have
largely been identified by binary names, we first compared species alternatives by citation
numbers, weighing PubMed searches more heavily based on the health-related aspects of this
research. When alternative species names had similar citation numbers, citation searches for
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genera were considered. Genera were not entirely conjoined unless all of the species identified
in our study had synonyms in the alternative genus. To retain access to information inherent in
the dual nomenclature system31, we continued to list other genera that were collapsed into the
first listed priority genus (as an example: Aspergillus/Emericella/Eurotium). When alternative
genera had citation numbers that were too close for comfortably naming one as a priority
designation, the original name identified by the NCBI BLAST searches was retained (as
examples, Sporidiobolus and Sporobolomyces).

2.4.11 Analysis and diversity measurements
Collapsed genera were placed in excel tables to show relative abundance of each for every
sample. Determination of capturing 95% of sample richness was measured using rarefaction
curves in iterations of 10 with an implementation of Rscript: alpha_rare.R in VAMPS32.
Phylogenetic trees, Morisita-Horn distance calculations, heat maps, genus level mycoprofile pie
charts and bar graphs were generated using VAMPS community visualization tools with a 0.1%
relative abundance cut off.
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Chapter 3. Considerations of protocol refinement and limitations for
fungal metagenomics
3.1

Introduction

Serving as the lead example for this study was the only other publication on the oral mycobiome
using a non-culture-based metagenomic approach: “Characterization of the oral fungal
microbiome (mycobiome) in healthy individuals” by Ghannoum et al23. However, when
replicating Ghannoum and colleagues’ protocols, several complicating factors were encountered
that began to confound our results. From DNA lysis, to sequence curation, to assigning
taxonomy, care had to be taken to ensure productive and reliable results. This chapter details
the measures taken to refine methods based on Ghannoum’s protocol, to challenge the current
standard for sequence assignments, to validate our approach, and to provide a roadmap for
tackling fungal mycobiome samples.

3.2

Evaluation of fungal lysis using common DNA isolation kits

In order to represent all fungi present in a sample from their DNA, sufficient measures must be
taken to adequately lyse cells. Fungi are encased in a resilient cell wall of chitin and in some
cases an additional polysaccharide capsule, which may even enlarge and enhance virulence
when they become threatened by a host, complicating extraction techniques33,34. Methods
described for fungal DNA isolation have historically included CTAB (cetyltrimethylammonium
bromide), which solubilizes cell walls, while denaturing proteins35 or freezing with liquid nitrogen
before grinding with a mortar and pestle36. Modifications are generally made to extraction
methods depending on the resilience of fungal spores or unique cell wall of the organisms being
studied. While the CTAB method provides the benefits of sufficiently removing carbohydrates
during DNA isolation, it is considered insufficient for cracking most spore types as well as some
mycelial fungi37.
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Often times a bead beating step is used to break these barriers that prevent access to gDNA.
The characteristics of the bead (smooth vs. rough and varying density based on chemical
composition), and its relative size to that of the sample and its cells, will often determine its
effectiveness in lysing a sample. For instance MP Biomedicals currently offers 16 different bead
compositions of “lysing matrices”, which are specifically designed to break cell types and extract
specific cellular components. Ghannoum and colleagues used MP Biomedicals’s FastDNA Spin
Kit, which employs a bead beading technique in its protocol. However, no clear indication was
made as to which lysing matrix was used. It was presumed that Ghannoum et al. used Lysing
Matrix A, as it is standardly supplied with the kit by default. A technical representative from the
MP Biomedicals company recommended a more robust bead that might release DNA from
fungal cells better than their own matrices commercially available in 2011. The bead suggested
was made of yttria stabilized zirconia which is an extremely high density material. At the time,
MP Biomedicals did not provide this bead, so it was specially ordered from an outside milling
company for testing on equimolar aliquots of cultured C albicans cells. A sample pack of several
other types of Lysing Matrices were also ordered for comparison purposes: Matrix A- garnet
flakes and one ¼ inch ceramic sphere (good for all sample types except soil), Matrix B- 0.1 mm
silica spheres (good for isolating bacterial DNA), Matrix E- 1.4 mm ceramic spheres, 0.1 mm
silica spheres, and one 4 mm glass bead (good for mixed tissue samples), Matrix Y- 0.5 mm
yttria stabilized zirconia spheres (good for lysing fungal tissue and spores), and Matrix B&Y- 0.1
mm silica spheres and 0.5 mm yttria stabilized zirconia spheres (combination of Matrix B and
Matrix Y). After DNA extraction with respective matrices, ITS1 PCR was performed as in section
2.3.4, but with BioRad iTaq™ DNA Polymerase. Surprisingly the matrix presumably used by
Ghannoum and colleagues (A) produced no detectable amplification, while matrices B, E, Y,
and B&Y showed clear amplification in an agarose gel. In all instances of sufficient gDNA
extracted for PCR amplification, there was absence of a dimer band < 100 bp, but when the
same gDNA was diluted there was presence of the dimer band. This begs the question of why
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lysing matrix A ITS1 product has no dimer band. It is possible that the band for this matrix is
present, but is below the limit of detection and remains unseen in an agarose gel. By combining
matrices B and Y, the brightest amplicon signal was obtained, implying that more gDNA was
intact and available for amplification than for other matrices. Further tests comparing matrices B,
E, and B&Y with amplification of ITS1 from saliva also showed evidence that the B&Y matrix
would give consistent results for relevant samples (data not shown), and that this combination
was the best option for the purpose of lysing fungal cells from saliva.

+

- A

B

E

+

+

-

N

Y

B&Y

Figure 3.1: Gel images of lysing matrices compared for C albicans ITS1 amplification, with
C. albicans dilutions to the right of each matrix depicted. + represents amplified C. albicans
positive control DNA, - represents reagent blanks, A, B, E, Y, and B&Y refer to matrices
described in section 3.1
The FastDNA spin kit was not without its weaknesses. At the elution step of initial extractions
there was a precipitate produced that contained small clear crystals. Amplifications performed
with such crystals did not result in visual DNA bands on an agarose gel. In order to determine
the cause of the crystal formation, the DNA isolation was performed without DNA and was
started at different places in the protocol, so that one chemical was added at a time in a
“backwards fashion”. For example, elution from the column was performed first, and no noted
crystals were formed. This showed that the elution buffer was not adversely reacting with the
tubes or column to create precipitate. In new tubes, the protocol was started at the addition of
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DNA binding matrix, and also at the addition of CLS-Y lysing solution. The protocol was followed
through to completion for each test. Only one of the tests produced crystals; the component
responsible for the precipitate was the CLS-Y lysing solution. There appeared to be a reaction
between CLS-Y and the elution buffer after several minutes of incubation. To remedy this, an
additional ethanol wash was added to the manufacturer’s protocol, which resulted in more
adequate removal of the CLS-Y before elution. Both ethanol washes in the modified protocol
were also advised to be performed thoroughly to ensure such removal. If washed well, the
eluate contained no crystals.

3.3

Comparison of additional extraction methods

While pure cultures of C. albicans perform exceedingly well in DNA isolation kits designed for
yeast38, it was important to remember that our samples contained many types of fungi, so it was
imperative to test kits with whole saliva to evaluate productivity of sequencing and to test for
inherent contaminants. Four extraction methods were compared using equal volume aliquots of
the same saliva sample: 1) the FastDNA Spin Kit Lysing Matrix A, 2) the FastDNA Spin Kit with
Lysing Matrix B&Y, 3) the UltraClean Soil (UCS) DNA Isolation Kit, and 4) the MasterPure Yeast
(MPY) DNA Purification Kit, following the manufacturer’s protocol or with modifications as
described in section 3.2. The resulting extracts were amplified with ITS1 primers and sequenced
using protocols detailed in chapter 2. After removing sequences composed of primers and
filtering for sequences characterized by an acceptable amount of mutations in primers,
homopolymers, “N” calls, and length, the FastDNA A matrix and UCS extraction methods
produced the fewest number of sequences (Table 3.1). Though Ghannoum and colleagues do
not report the 454 region size used, the relatively low number of total sequences obtained in
their study is in concordance with low sequence counts obtained for FastDNA lysing Matrix A
presented here. The MPY method showed relatively high numbers of reads in the reagent
blank, but should be tested further as it performs well in other studies38. Our modified FastDNA
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B&Y method yielded the greatest percentage of productive sequences and showed that
contamination would not confound results, confirming results of comparisons between lysing
matrix A and B&Y from section 3.2 and providing support for our modified method in all
downstream experiments.
Table 3.1: Comparison of four extraction methods on whole saliva

3.4

Recognition and elimination of primer artifacts

The first attempt at sequencing the healthy mycobiome included 5 barcoded subjects over 1/8
454 Picotiter plate. This region produced a total of 74,693 raw reads. Many of the raw
sequences were run through NCBI BLAST to confirm their identity as fungal DNA. Nearly all
sequences were assigned to an “uncultured fungal clone”, suggesting the possibility that several
new taxa may have been sequenced. After a closer inspection, these sequences consisted
solely of concatenated primers averaging ~65 bp, but could reach more than 200 bp in length.
The presence of primer artifacts accounted for ~95% of sequences and was the primary cause
for reduction of total counts to a mere 4,509 classifiable sequences. As the majority of these
artifacts were relatively small compared to the amplicon size of interest (~200-600 bp after
addition of fusion primers39), measures were implemented as part of the library preparation
procedure to remove them prior to sequencing. Because not all primer artifacts were eliminated
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through size selection, a custom perl script was created to remove them in the first step of the
pipeline.
One additional library preparation step for the removal of small fragments was the Sage Science
Pippin Prep™. A 2% Agarose Gel Cassette was chosen in order to collect fungal ITS1
fragments 160 bp or greater. This length was determined by adding an extra 60 bp for barcode
and adapter sequences (trimmed before the 100 bp filtering step) to the minimum number of
nucleotides required for ITS1 sequence length. The Pippin Prep™ employs pre-poured agarose
gels and electrophoresis to collect custom sized fragments by changing electric current to direct
DNA into an elution module. While this step greatly reduced the amount of primer artifacts, an
additional library preparation step was sometimes needed if small fragments persisted.
AMPure® XP beads were employed for their size selection properties, which work by
preferential binding of DNA to solid-phase reversible immobilization paramagnetic beads in the
presence of polyethylene glycol and salt. For the majority of samples these two additions were
adequate for removing primer dimer. However, not all clinical samples are created equal, and
some produced fragment profiles that were comprised almost completely of primer dimer. No
matter how many additional AMPure® XP purifications were performed, they were inadequate
to remove dimer yet retain sufficient amounts of ITS1 DNA for sequencing. Last, in order to

Figure 3.2: Bar graph of
improved sequence
retention applied to 6
healthy subjects with
the improved library
preparation
modifications and
bioinformatics pipeline
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remove any remaining primer concatenations, especially those that were within the length of
amplicon interest, a custom bioperl script was implemented. The bioperl script creates a
“database” out of sequences collected from saliva samples and uses BLAST to query for the
commonly found dimer, filtering sequences that it matches. Application of these modifications to
a deep sequencing effort of 6 healthy subjects illustrated the improvements in loss due to dimer
(Figure 3.2).

3.5

Using upstream analyticals to predict successful sequencing

One of the challenges encountered with samples in restricted availability and/or limited
quantities is that they may be fully consumed in processing if not handled very carefully. Several
assessments emerged as indicators of such samples and provided predictive values of success
early in the library preparation workflow. Another quality control measure for a sample,
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NanoDrop measurement, comes after the gDNA extraction step and indicates potential for
amplification. Low NanoDrop values (≤13 ng/µL) consistently represented samples that proved
difficult for detection of quantifiable amplicons before pooling samples for sequencing. Low
values for saliva samples could be caused by user errors during the extraction protocol
(inadequate ethanol washing, failure to remove fully remove layers containing PCR inhibitors),
or limited cell count in the sample source. Figure 3.3 shows the distribution of samples with a
concentration of less than 200 ng/µL gDNA for all patient samples (further characterized in
chapters 5 and 6). The average NanoDrop reading for samples that exhibited clear amplification
of ITS1 fragments was 55.1 ng/µL (range 10.5 to 189.3, n=106). The average NanoDrop
reading for samples that exhibited no signs of amplification was 7.75 ng/µL (range 2.8 to 12.8,
n= 24). To eliminate MID sequence as a variable affecting amplification success, NanoDrop
values were also plotted by MID number. Only MIDs 1 and 11 showed a consistent
predisposition toward successful amplification, while all other MIDs evenly shared successful
and unsuccessful amplification of ITS1.
A second assessment point is the relative amount of amplification product. In cases where PCR
amplification is low, samples should be handled with extra care during artifact removal steps.
For instance, saliva volumes at < 0.75 mL did not produce amplicon signals in gel
electrophoresis, so quantities under this amount should be considered carefully before
subjecting to library preparation steps that further reduce amplicon amount. We continued to
notice that preferential amplification of dimers occurred when amplification of ITS1 products was
low and hypothesize that if fungal gDNA content is low, increased care is needed to remove the
high amounts of dimers that accompany limited ITS1 amplicons. Skipping the agarose gel and
Pippin Prep™ steps increases the likelihood that more product, however little, may be retained.
Proceeding directly to the Bioanalyzer can give an indication of whether a sample is expected to
fail and is therefore not as good an investment of time and reagents as other samples might be.
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For example, Bioanalyzer readings that continued to show predominant primer dimer peaks,
after up to as many as five AMPure® XP purifications, consistently resulted in ITS1 fragment
removal below the limit of detection in the Bioanalyzer, while small dimer peaks were still
present. These samples were thus unable to be sequenced due to loss of quantitative data that
allows for equimolar pooling of multiplexed samples. If dimers must be removed, an AMPure®
XP purification could be added as long as the volume of elution material is decreased to help
concentrate the amplicon in the eluate.

3.6

Database selection

One of the most important factors in presenting reliable interpretation of sequencing results is
choosing a database that includes the best representation of relevant taxa. Ghannoum and
colleagues used the Assembling Fungal Tree of Life (AFTOL) and NCBI databases for analysis.
In order to assess other recommended databases40 for reliability and ease of use, four
databases were queried with a C. albicans ITS1 sequence (completed in February 2012): 1)
BoldSystems ITS, 2) mycologylab.org, 3) UNITE, and 4) the Fungal Metagenomics Project
(FMP). As a top hit, BoldSystem ITS returned Mystrium oberthueri, an ant, with an e-value of
6x10-23, while UNITE returned Amanita virosa, a poisonous basidiomycete fungus at an e-value
of 3x10-30. The optional addition of INSD (including GenBank, DDJB, and EMBL) in UNITE
returned uncultured Ascomycota at 1x10-138, which is the correct phylum for C. albicans, but is
not specific enough as a top hit considering its biomedical relevance to this study. The FMP and
mycologylab.org both returned C. albicans as a top hit with respective e-values of 1x10-130 and
2x10-88. Such differences in accuracies of these two databases compared to UNITE and
BoldSystems ITS is likely due to the composition and focus of the databases. BoldSystems ITS
offers a disclaimer: “There are very few ITS records on BOLD so most queries will likely not
return a successful match”, while UNITE comprises plant pathogens and symbionts.
Mycologylab.org comprises only curated human/animal pathogenic fungal species, while FMP
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offers a curated search of Genbank, which eliminates sequences with designations to
“uncultured” and “environmental” descriptors. The removal of primer regions from the ITS1
sequence returned the same results for both mycologylab.org and the FMP. For BoldSystems
ITS, search results were improved with primer removal, so that at least the correct identification
to Ascomycota was made, although at the very weak e-value of 8x10-8. Primer removal in
UNITE resulted in a top hit to Thelephora alnii at e-value = 2x10-21 and with addition of INSD, C.
albicans was returned at 1x10-117. These data made it clear that FMP would provide a consistent
database that contained relevant results with strong e-values with and without primer removal.

3.7

Removing non-informative sequences by length

To be considerate of other FMP users and respect the Project’s computational resources, we
wanted to eliminate non-informative sequences as much as possible before submitting
sequences to be classified. All sequences from the 6 healthy samples that were deepsequenced for core mycobiome analysis, were partitioned into length classes (post-adaptor,
primer and MID removal) to determine the relevance of each category by its assigned FMP evalues (Table 3.2).
For the smallest size class (0-99), there were no returns with e-values better than 1x10-15, a
poor e-value threshold that represents alignment of reference sequences to short flanking
regions. We determined that sequences less than 100 bp should be removed before submitting
to FMP because filtering by length occurred before removal of the reverse primer in QIIME. A
bioinformatic step to remove sequences in the 0-99 bp category was implemented using Galaxy
to increase efficiency in assigning taxa in FMP. The sequences in the 200-299 bp and 300-399
bp categories were most fruitful for providing informative sequences. Sequences with lengths
outside of these two categories are either generally a result of non-specific amplification or may
represent new, medically relevant fungi. Distinguishing between the two hypotheses can be
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revisited in the future and will be made easier as more reference fungal sequences are
deposited into databases.
Range

Number

%of total

Evals <1E-15

%Evals <1E-15

0-99

7005

1.253281

0

0

100-199

5127

0.917283

2479

48.35186

200-299

382161

68.37331

365925

95.75153

300-399

163767

29.29993

162735

99.36984

400-499

787

0.140804

106

13.46887

86

0.015386

3

3.488372

558933

100

531248

95.04681

500+
total

Table 3.2: Distribution of sequences lengths obtained from 6 deeply sequenced healthy
mycobiomes and their proportion of poorly aligning sequences.

3.8

Assessing reproducibility and stochastic effects

An additional concern in microbial sequencing is the potential for stochastic effects. While PCR
is the main focus of chance events and bias in sequencing experiments41, other variables still
play a role in the randomness of results. To minimize the concern of stochastic effects due to
PCR, reactions were performed in triplicate and a low annealing temperature was used to
accommodate for potential mutations in primer binding sites. Four separate iterations of library
preparation were performed on extracted fungal DNA from 6 different healthy individuals to
assess variables introduced by differences in template amount, and individual scientist in a
separate location for PCR preparation: 1) 125 ng gDNA template, preparer A, 2) 250 ng gDNA
template, preparer A, 3) 125 ng gDNA template, preparer B, 4) 250 ng gDNA template preparer
B. Between 52 and 76% of the taxa in the four iterations for a single sample (post-filtering
through dimers script, DeconSeq, and QIIME) were not reproducible for more than one iteration
(data not shown). At first glance this suggested that variables may indeed have an effect on the
representation of taxa. In the cases of two of our samples, only 2% and 1% of taxa were present
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in all iterations, respectively. However, when considering the number of sequences representing
the taxa present in all iterations of a single sample, they constituted the majority of the data
(Figure 3.4). As an example, the remaining sequences that appeared in at least 3 out of 4
iterations for sample 50 belonged to 120 taxa, but any of these individual taxa were at most
represented by a total of 380 sequences (0.01% of total sequences collected for combined
iterations of sample 50).

Figure 3.4: Pie chart
of percentage of
sequences
representing taxa
shared across all four
iterations for 6 healthy
subjects

To assess biases due to template amount vs. individual scientist and location of PCR
preparation, iterations sharing a common parameter were compared, (for example, both 250 ng
gDNA template amounts vs both 125 ng gDNA template amounts). The hypothesis was that if
biases were created by introducing a new parameter, then there would be more shared taxa
between two common parameters than between two random parameters. In every instance, the
average shared number of taxa between two common parameters never exceeded the average
number of shared taxa between random parameters (Figure 3.5). This meant that using a
smaller starting amount of gDNA template would not significantly affect the outcome of the
results, potentially allowing for more experiments to be performed with leftover gDNA, and
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potentially beneficial if complications were experienced at any point in the pipeline. These data
also provide evidence that sample handling in separate locations and by separate scientists will
not affect the outcome of experimental results any more than random effects due to the nature
of such experiments. These data, combined with the fact that these shared taxa represent less
than 5% of all sequences obtained, provides support for removal of minor components from
mycoprofiles to get an accurate representation of reproducible and legitimate community
membership. In hindsight, these numbers were also influenced by poor taxonomic assignments
to reference sequences and redundant genera (discussed in 3.9 and 3.10, respectively), which
reduce their proportion to less than 5% of all data obtained for these samples and indicate that
biases for our processing and handling were situationally minimal.

Figure 3.5: Bar graph of average representation of taxa shared between 2
iterations of a sample across common PCR preparation parameters tested
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3.9

Identifying legitimate taxa

3.9.1

Using DeconSeq to remove contamination

As metagenomic amplicon surveys attempt to universally amplify from multiple cell sources,
non-specific amplification often occurs. Degenerate primers and lower annealing temperatures
are measures taken to broadly target all DNA sources of interest, but also promote irrelevant
amplification of other sources that are commonly found in the niches with cells of interest. A tool
to remove sequences matching well characterized sources of bacterial and human DNA is
needed to remove such sequences as to simplify downstream analysis. DeconSeq was
therefore implemented for removal of sequences matching custom alignment and query
coverage thresholds. A plot of matches to DeconSeq databases showed contamination at >80%
alignment with query coverage >5%. Two settings were chosen to see how they would affect
the taxonomic representation of sequences 1) a “loose” setting at ≥80% alignment with ≥10%
query coverage and 2) a “strict” setting at the default setting of ≥94% alignment identity and
≥90% query coverage. Loose settings removed some sequences matching to relevant oral fungi
such as Malassezia, Candida, and Alternaria with e-values to these genera of as low as 1x10168.

Strict DeconSeq settings eliminated only sequences that were illegitimately classified (e-

values for fungal matches as great as 1x10-4). This setting allowed for fine tuning of our dataset,
while conservatively retaining relevant fungal taxa, and was applied to all downstream sample
analyses.

3.9.2

Using a Blast statistic to develop a taxonomy based ID screen

While recent oral mycobiome studies have used alignment identity thresholds (generally 97–
98%) to assign species identifications to ITS1 sequences, the suitability of this practice has
been questioned42. We found that this standard resulted in reductions in representation of taxa
that were abundant, frequent and potentially biologically meaningful. As an example, of the
18,914 sequences assigned to Emericella nidulans, an alignment threshold of 97% eliminated
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13,601 (72%), leading to an underrepresentation of a known opportunistic pathogen. Thresholds
of 90% are sometimes used for genus-level identifications, but these also have potential
problems. We investigated E-value thresholds as a supplemental identification metric by
mapping increasingly stringent thresholds (representing an arbitrary doubling, tripling and
quadrupling of the exponent) onto a subset of sequence assignments for a single subject (#50,
the most diverse individual sampled in our study, Figure 3.6).
Figure 3.6 summarizes the effects of increasing E-value thresholds, where Expect-value
number denotation represents the exponent (1x10-21 = E-21= 1E-21). The least restrictive E-21
removed 134 genera assignments, representing sequences that were at counts less than 4 and
plant derived sequences. Other assignments in this interval were to the genera Neopaxillus,
Mortierella, and Ramicandelaber and were characterized by poor E-values (>−21) driven by 18S
and/or 5.8S alignments; these three taxa appeared in only marginally better intervals at E-24.
Only 4% of the sequences removed by this threshold represented genus level assignments also
identified by much stronger matches in the same individual (e.g. Saccharomyces, Pichia,
Cordyceps, Cortinarius). We concluded that there was no loss of fungal genera by imposing the
E-21 threshold in curation of the taxon assignment dataset. At the most restrictive interval of E64 to E-84, neither sequences below the abundance threshold (4 counts), nor sequences
derived from plants were present. Assignments that did not reach genus level resolution were
present, but minimal (4%). The vast majority of genera assignments (96%) were also included in
even stronger E-values, lending support to the conclusion that taxonomic assignments in this
interval represented authentic fungal components. As evidence of assurance in taxon
identifications, 99% of the sequence assignments in this entire dataset (sample #50) were
stronger than the E-63 restrictive threshold, and 97% met an E-95 threshold suggested
previously as a basis for confidence in genera assignments43.
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Our goal was to choose a threshold from intermediate intervals that would achieve both
confident identifications and “conservative flexibility” for natural variants. In the E-22 to E-42
interval, sequences below the count thresholds and ones based on plant identities remained;
almost half (46%) of the sequence assignments were to three genera with no E-value stronger
than E-42 in the entire sequence set. Included in this group were the plants Osmorhiza (NCBI
BLAST match to carrot,) and Tilia (NCBI BLAST match to tomato). The genus Coniosporium (a
rock-inhabiting fungus) was assigned to sequences in this interval based on a poor alignment;

Figure 3.6: Bar graph of distributions of indicators for relevant and irrelevant taxonomic
assignments at multiple e-value classes
however, based on strong alignment and E-value to an uncultured fungus, this most likely
represented a legitimate fungal sequence that cannot be assigned with confidence to any genus
based on current reference databases. About a quarter of the sequence assignments (27%)
were to the less precise phylum level (Basidiomycetes, endophytic). The percentage of
sequence assignments to genera also included in much stronger E-values (−52 through −135)
increased to 19%, distributed over five genera (Candida, Cortinarius, Cryptococcus,
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Mycosphaerella, and Pichia). In the next most stringent interval of E-43 to E-63, plant-derived
assignments disappeared and phylum/class assignments were reduced, all to the
Dothiodiomycetes. More than half (52%) of the sequence assignments were to five genera that
were also included in much stronger E-value groups, Candida, Malassezia, Mrakia,
Mycosphaerella, and Pichia. Based on these findings, we adopted an E-value threshold of ≤−42
for inclusion in the curated assignment list. We also note that the alignments that met this
threshold had bit scores that were ≥ the 200 bit score filter adopted in a study for ITS2
amplicons19. We confirmed the validity of our E-value threshold by evaluating its performance
against sequence sets for all five remaining subjects. Whether the subject represented
individual variation similarly to the highly diverse subject 50 or a less diverse community such as
subject 51, the results were still fully consistent with the details provided in this section with
respect to the kinds of inappropriate taxa that were eliminated. The finding that E-values
significantly lower than those routinely deemed as acceptable could still represent spurious
assignments to fungal genera is an important one that can result in misleading interpretations
about fungal community members. An intriguing aspect of the E-value threshold is that this
single filter effectively removes low abundance representation, plant-derived amplicons,
unclassifiable sequences, and those identifications based on short conserved sequences or
otherwise poor alignments.

3.10

Creation of a roadmap for improved nomenclature results

Genera identified in the top 20 rankings also provided an opportunity to consider the challenges
that nomenclature posed to the curation of taxon assignment datasets, subsumed under the “1N
= 1F” (One Name One Fungus) initiative. We focused on genus level assignments because they
represented very strong probabilities of non-random matches, and most of the taxonomic
assignments in this level were derived from multiple reference sequences, often including type
species. We collapsed genus assignments by considering alternate names, common knowledge
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of the teleomorph (sexual form) and anamorph (asexual form) pairs, previously published
recommendations, and the more specific taxonomy assignment in our dataset. We also created
our own biblioinformatic examination of “common usage” (Table 3.3) as suggested by
Hawksworth30. Our usage table was based on assignments in our own dataset, and is by no
means comprehensive. In the nomenclature deconvolution process, we referred by necessity to
species names as well as genera in considering sexual/asexual pairs. Moreover, given the
human and biomedical orientation of this project, we added NIH NCBI publications to our
biblioinformatic metrics, as well as consideration of those genera known to be common oral
inhabitants, in deciding which genus to list as the “priority” one in conjoined groupings. In order
to avoid the loss of information inherent in dual nomenclature31, we listed major constituents of
the conjoined genera.

Table 3.3: Common usage survey on pairs of competing genera names1
Name2

Google

BSM

7,300

Google
Scholar
977

Trichosporon
pullulans
Trichosporon
Lewia infectoria*
(T)
Chalastospora
gossypii
Chalastospora
Lewia*
Pichia jadinii (T)

223,000
13,200

18,300
125

356

691

7

3,660
13,400
8,100

21
299
450

5
44

Pichia

963,000

85,000

503

Debaryomyces
hansenii (T)
Aspergillus
nidulans (A)
Aspergillus

154,000

7,200

501,000

45,200

5,280,000 629,000

PubMed Name2

Google

32

Guehomyces
pullulans

7,940

Google BSM PubMed
Scholar
113
7

1,473
1

Guehomyces
Alternaria
infectoria (A)
Alternaria
malorum

11,400
6,140

130
471

3,020

27

3

1,390,000
84,400

135,000 788
11

3,098
0

106,000
120,000
34,500

30
1
14,500
2,730

813
130

90,400

3,160

282

144,000

5,330

1

1,047

3
7
16

Alternaria
Cyberlindnera
jadinii
Cyberlindnera
Candida utilis(A)
440
Candida famata
(A)
4,079
Emericella
nidulans (T)
34,549 Emericella

1

5

149

8
35

371

Searches conducted on 4/3 and 4/4 2013; Bold names are ones selected for this study. When taxa
could be assigned to multiple genera, the default selection was concordance at lower taxonomic levels.
2
(A) indicates anamorph; (T) indicates teleomorph
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Cytospora
chrysosperma
Cytospora
translucens
Cytospora* (A)
Filobasidium
floriforme (T)
Filobasidium (T)

5,580

795

3

Valsa sordida

5,360

422

5

839

14

0

541

11

0

105,000
3,310

3,140
187

95

33
2

424,000
24,600

2,230
3,710

8,150

1,120

93

31

Valsa
translucens
Valsa* (T)
Cryptocccus
albidus (A)
Cryptococcus
(A)
Cryptococcus
macerans (A)

1,220,000

92,400 868

9,192

5,270

168

3

Trichoderma
37,100
koningii
Trichoderma (A) 952,000
Neofavolus
28
mikawai
Neofavolus
389
Phoma
8,370
glomerata(A)
Phoma
792,000
Phoma pratorum 645
(A)

5,590

98

160,000 515
1

4,083
0

1
810

0
18

84,500 665
3

425
0

Penicillium
5,290
radicum (A)
Penicillium
1,400,000
Mycosphaerella 1,300
communis
Mycosphaerella 1,960
lateralis (T)
Mycosphaerella 395,000
Ustilaginoidea 380,000
virens
Ustilaginoidea 389,000
(A)
Curvularia lunata 56,600
(A)
Curvularia
1,990
verruculosa (A)
Curvularia (A)
185,000
Coprinus radians5,370

251

0

235,000 989
9

10,053
1

56

0

24,300 700
1,120

418
18

1,310

19

Cystofilobasidium 1,060
macerans (T)
Cystofilobasidium 6,830
(T)
Hypocrea koningii 11,600

17

Hypocrea (T)
Polyporus
mikawai
Polyporus
Peyronellaea
glomerata (A)
Peyronellaea
Pyrenochaetopsis
pratorum
Pyrenochaetopsis
Talaromyces
radicus (T)
Talaromyces
Uwebraunia
commune
Uwebraunia
dekkeri
Uwebraunia
Villosiclava virens

149,000
1,170

5,550
13

273

290
0

489,000
2,230

20,300
64

502

288
1

5,300
30

318
1

7

9
0

1,980
71

9
1

96,500
180

7,770
5

87

3

16,200
10,700

56
25

16

1
2

Villosiclava (T)

13,400

29

3

2

Cochliobolus
lunatus (T)
Cochliobolus
verruculosus (T)
Cochliobolus (T)
Coprinellus
radians
Coprinellus
flocculosus
Coprinellus
micaceus
Coprinellus
Coprinopsis
radiata
Coprinopsis
Engyodontium
album (A)

36,700

1,140

54

2,680

23

0

194,000
2,910

17,300
71

9,850

18

0

17,500

108

0

59,700
6,250

522
28

36

150,000
6,320

1,820
278

74

571

1
75

86

1
0
199
1
1

194

61
177

45
0

183

131

358
5

24
0

7

Coprinus
flocculosus
Coprinus
micaceus
Coprinus
Coprinus
radiatus
Obsolete?
Tritirachium
album (A)
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0

28

8,210

219

197

4

20,100 265
193

549
2

4,580

27

51,200

831

4

642,000
7,830

20,600 766
323

642
18

Synonym
18,800

1,910

36

Engyodontium
Erythrobasidium
hasegawianum
Erythrobasidium
Funneliformis
caledonium
Funneliformis
Gliomastix
murorum (A)
Gliomastix

8,450
3,700

416
97

36

14
8

10,500
6,020

229
6

55

19
0

16,600
11,300

126
419

1

7
3

9,610

1,130

29

15

Lenzites
betulinus(a)
Lenzites
Ramularia
grevillana (A)
Ramularia (A)
Ramularia
eucalypti
Discostroma
fuscellum (T)
Discostroma (T)

20,701

1,111

64,000
1,200

4,050
17

147

27
0

78,400
271

4,480
5

254

22
0

476

13

9,130

145

Sporidiobolus
pararoseus (T)
Sporidiobolus
Dioszegia
hungarica
Dioszegia
Gibellulopsis
nigrescens (A)
Gibellulopsis

3,310

478

17,000
3370

478
88

116

58
4

6160
9410

256
36

36

18
0

11,700

59

2

3.11

15

0
37

1
11

0

Tritirachium
30,000
Rhodotorula
1,940
hasegawae(A)
Rhodotorula
304,000
Glomus
19,400
caledonium
Glomus*
230,000
Acremonium
6,740
murorum (A)
Acremonium
296,000
Synonyms
Trametes betulina 1,640

2,720
62

Trametes
459,000
Mycosphaerella 11,400
fragariae (T)
Synonyms

21

49
3

27,200 369
1,040

1683
23

26,300 583
194

994
1

26,000 408

1,455

26

0

21,500 348
587

902
3

0

Seimatosporium
lichenicola
Seimatosporium
(A)
Sporobolomyces
shibatanus (A)
Sporobolomyces
Cryptococcus
hungaricus

3,700

69

7,310

437

1,600

437

79,200
3010

6,650
97

Verticillium
nigrescens (T)
Verticillium

6280

297

3

712,000

63,400 496

787

53

12
2

222

209
5

Concluding remarks

Herein we have proposed a roadmap for analysis of ITS1 amplicons and have provided
empirical support for recommendations made. Testing our methods through technical iterations
showed that there was no effective bias in genera between PCR preparer and amount of
template used. We have challenged the current standard for fungal mycobiome studies by
implementing an extraction method that is efficient for obtaining DNA from spores, identifying an
appropriate database for obtaining reliable fungal assignments, employing empirically
determined parameters to remove and refine the genera represented in our dataset, and
collapsing fungal genera to ensure genera were not inflated by synonyms names.
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Chapter 4. Characterization of the healthy oral fungal microbiome
4.1

Introduction

At the time this study began, the healthy oral fungal microbiome (mycobiome) had been
described by a single study by Ghannoum et al 2010, in which 13 components were presented
as common occupants of the oral cavity. Following the methods in chapter 2, our results were
concordant for the majority of genera, but also revealed several novel genera. This chapter
summarizes our findings in the healthy mycobiomes of six individuals using a deep sequencing
approach. The similarity of our findings to those in the study by Ghannoum and collaborators,
although using a very different protocol, offers support for the analyses we employed.

4.2

Application of curation rules to healthy subjects

Raw reads totaling 853,653 provided 473,493 sequences after applying our bioinformatics
pipeline; approximately 55.5% of original sequences remained. A first glance at the retainment
percentage of Ghannoum and collaborators’ that was reported (87% after applying their
pipeline) suggested that our pipeline was very strict in comparison. However, after closer
inspection, the percentages of unclassified fungi (sequences resulting in automated taxonomy
that were only as specific as the family level) were drastically different between studies.
Removal of unclassified sequences in our study resulted in a minor shift in the percentage of
sequences retained (55.5% to 54.6%). Removal of unclassified sequences from Ghannoum and
collaborators’ analysis vastly impacted the percentage of sequences retained, reducing them
from 86.8% to 48.5%. This suggests that our rate of correctly identifying fungal mycobiome
components is on par with (or slightly better than) other similar studies. The reason for such a
drop in reliable sequences in Ghannoum et al.’s study was likely due to a number of reasons: 1)
Using a top-hit BLAST approach in reporting taxa caused matches to “unclassified and
“uncultured” Genbank sequences often deposited from metagenomic studies, which would
otherwise be classifiable 2) Using databases non-specific to fungi caused identifications to
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Pongo and Campylobacter, misrepresenting the proportions of fungi in the oral cavity with nonfungal classifications. While our initial experiments were abundant in concatenated primer
sequences (~95% of all sequences), implementing the pre-sequencing AMPure® XP and Pippin
Prep™ steps greatly reduced the proportion of these artifacts in the dataset, leaving only 4.7%
of sequences to be removed by our post-sequencing perl script. A closer look at the sequences
filtered in this step shows a reduction in unclassified “Fungi” of ~80%. These modifications have
vastly improved the productivity of sequencing space and reduced effort toward analyzing
uninformative artifacts.
The DeconSeq step was used with a strict cutoff of 90% query coverage and 94% alignment
identity so that only those sequences that matched well to the contamination databases would
be eliminated. As a result, none of the sequences filtered by this method reached the e-value
threshold of 1E-42, and are clearly nonspecific products of universal amplification from a saliva
sample with different kinds of gDNA. Only 1,352 sequences were filtered with this method.
Perhaps using a lower stringency for contamination would eliminate even more sequences with
poor e-values before submitting to the fungal metagenomics project in the final stages of
analysis. The top 20 taxa were not affected by this step.
The QIIME split_libraries step had the greatest effect on sequence numbers filtered (87% of
sequences lost at this step). The majority of sequences removed in this step were due to
fragment size <100 bp. The median e-value increased to 1x10-21 from 1x10-138 at the DeconSeq
step, which was unexpected because filtering short sequences should improve the median
match statistic and the median e-value for sequences filtered was 2x10-4 (appendix table 1).
However, we found the e-value to be affected by the removal of trimming primer sequences,
which acted as anchor sites to reference sequences, thereby weakening the match statistic to
all sequences during the QIIME step. In the length filtering step, the pipeline restored the
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median e-value to a more acceptable value (1x10-123), suggesting that sequences <100 bp that
still remained after QIIME were the greatest affecters of e-value post-QIIME.
Of all steps in the pipeline, the e-value filtering step had the greatest effect on the number of
genera represented across samples. Only 32% of raw sequence genera were retained at this
step, likely due to elimination of sequences that were illegitimately forced to match reference
sequences to which they did not strongly align. This step was critical for removal of non-fungal
sequences that contained 18S regions (plant), as evidenced by the elimination of Lysurus,
which was the third most represented genus in the top 20.
Total genera were reduced from a maximum of 732 down to 144, eliminating the majority of
singleton genera and reducing the representation of spurious assignments. Ten of the top 20
genera were eliminated after curation rules and 12 were affected by nomenclature
deconvolution (Figure 4.1). Of the 17 genera listed in the fully curated top 20 (Figure 4.1), 12
were affected by nomenclature deconvolution. The genus Cyberlindnera was exclusively
represented by its synonym, Pichia jadinii, so the former sequence counts were attributed to the
genus Pichia. In turn, the genus Pichia was represented by three species: jadinii, kudriavzevii,
and membranifaciens, all of which have the other names of Candida utilis, Candida krusei, and
Candida valida, the respective anamorph forms. The Pichia sequence assignments were
collapsed into Candida; the pair accounted for 0.2%–36% of sequences in individual subjects
(Figure 4.3), a range in good agreement with the previously published study of Ghannoum and
collaborators. While not every described species in the genus Pichia has a Candida counterpart,
all Pichia identified in our sequence study did and were therefore appropriately combined.
Across the six subjects in our study, sequences assigned to Pichia represented 99%, 43%,
81%, 7.7%, 6.7% and 0% of the combined Candida plus Pichia sequences (Figure 4.3). The
teleomorphic genus Gibberella was often accompanied by its anamorphic genus Fusarium at
identical E-values in the top 4–5 NCBI BLAST hits. In the vast majority of these cases, there
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were no species assigned to Gibberella, but assignments to Fusarium culmorum were common.
In other Gibberella assignments, the species have Fusarium anamorph pairs. Gibberella
sequence assignments were collapsed into the genus Fusarium. The genus Emericella was
exclusively represented by the species nidulans, a synonym of Aspergillus nidulans, so the
former sequence counts were attributed to Aspergillus. Assignments to genus Eurotium were
also reassigned to Aspergillus, its priority genus44. Likewise, since the genus Lewia was
exclusively represented by the species infectoria, the teleomorph form of Alternaria infectoria,
we collapsed these sequences into Alternaria. The synonymous teleomorph genus Davidiella
was collapsed into its anamorph genus Cladosporium30.
Nomenclature considerations for less abundant taxa also affected the top categories (Figure
4.1, panel B). The teleomorph genera Filobasidium (F. floriforme) and Cystofilobasidium (C.
macerans) were collapsed into the more commonly used nomenclature of its paired anamorph
genus Cryptococcus30. Trichosporon was represented by the species pullulans, another name
for Guehomyces pullulans; both sequence assignments were included under the genus
Trichosporon (common usage). The anamorph species Cytospora chrysosperma (also called
Valsa sordida) and Cytospora translucens were combined into the teleomorph genus Valsa. The
genera Lenzites, Penicillium, and Phoma also rise in the listings by cumulative abundances.
Many other assignments that were also affected by nomenclature deconvolution, but not in the
top 20, are included in Table 3.3.
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Figure 4.1: Stepwise effects of bioinformatics pipeline and nomenclature deconvolution on A)
basic sequence statistics and B) on the top 20 represented genera of the six combined
healthy individuals. Yellow highlighting represents genera removed that were found to have
poor alignment. Gray represents plant-derived sequences incorrectly assigned fungal
identity. Blue represents fungal assignments above the genus level.

4.3

Comparison of core mycobiomes

Ghannoum and collaborators23 identified components of the healthy oral mycobiome using a 1%
abundance cutoff with an average of 1,700 reads per sample, likely missing community
members in low abundance. A deep sequencing approach must be used to identify core
members observed frequently at both low and high abundances to assess their role in health. Of
the 34,049 sequences, 36.1% used in Ghannoum’s study were assigned to an ambiguous
group of “unculturable” fungi. One possibility is that these assignments were made to other
environmental survey-based submissions in the NCBI database that omit fungal taxonomy. We
hypothesized that application of our extraction method and curation steps would discover novel
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oral commensals, reduce the proportion of “unculturable” assignments, and refine the core oral
mycobiome through more comprehensive profiles.
Fourteen genera met qualifications as core community members in health in our study (Figure
4.3). Included in these were all but three core oral genera present in Ghannoum’s study. The
shared genera included Candida, Cladosporium, Aureobasidium, Alternaria,
Aspergillus/Eurotium, Fusarium/Gibberella, and Cryptococcus. The three genera absent from
our representation of the core mycobiome are Teratosphaeria, Saccharomyces, and Glomus. In
this study, Teratosphaeria may have been subsumed in a category such as “unclassified
Capnodiales” or the genus Mycosphaerella, which is polyphyletic and includes some species of
Teratosphaeria. Even still, only 56 counts of Mycosphaerella and 7 counts of “unclassified
Capnodiales” were observed. Saccharomyces was represented in 3 subjects, but accounted for
only 0.1-0.5% of sequences in each sample. Twenty-four counts of Glomus were obtained from
two samples. Relatively high counts of Saccharomyces and Glomus assignments were
observed in our raw dataset, but the application of the sequence curation pipeline greatly
reduced these numbers. Our findings suggest that Glomus may not be a legitimate core
member as originally proposed by Ghannoum and colleagues, and that species of
Saccharomyces are markedly underrepresented compared to other core genera.
The comparison between the results of Ghannoum and colleagues and our study is summarized
in Figure 4.2. Ghannoum and colleagues reported thirteen components in the basal mycobiome:
Alternaria, Aspergilllus, Aureobasidium, Candida, Cladosporium, Cryptococcus, Dothioraceae,
Eurotium, Fusarium, Glomus, Saccharomyces, Saccharomycetales, and Teratosphaeria. Of the
eleven that were identified at the genus level, our study also found eight of these in more than
half of the subjects (genus followed by frequency and range): Alternaria/Lewia (100%, 0.01–
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Figure 4.2: Venn diagram of the relationships between results from the two studies of the
human oral mycobiome. Shared genera are indicated in the overlap (purple font) between
the current study (Dupuy et al.27, red font) and the previously published study (Ghannoum et
al.23, blue font). Genera in brown are shared between the two studies but failed to meet
thresholds in one or the other.

7.07%), Aspergilllus/Emericella/Eurotium (100%, 0.001–10.27%), Candida/Pichia (100%, 0.12–
35.86%), Cladosporium/Davidiella (100%, 0.06–8.26%), Cryptococcus/Filobasidiella (100%,
0.05–0.81%), Fusarium/Gibberella (83%, 0.01–18.35%), and Aureobasidium (67%, 0.004–
0.08%). The genera Saccharomyces (50%), Epicoccum and Phoma were also shared, but were
below thresholds in one study or the other. Epicoccum is found in indoor house dust samples45,
has been identified in air samples in buildings, including in the Northeastern U.S. where all of
our subjects lived46, and is a well-known air allergen. Phoma and Epicoccum were also
identified as components of indoor fungal composition in temperate zones47, and may represent
environmental acquisitions specific to geography. While Epicoccum has not been associated
with human infections, it has been identified as a source of allergens, and some species

52

possess antifungal activity against pathogenic plant fungi. Phoma species were found to be
causative of infection in a transplant recipient48.

Figure 4.3: Frequency, abundance, and distribution of genera occurring in
>50% of the six subjects. Genera ordered by frequency of occurrence, with
normalized representation and sequence counts (columns 2, 3, 4). Heat
map depiction (columns 5–10) summarizes qualitative and quantitative
distribution of genera in six individuals (50, 51, 52, 54, 56, and 57) and
depth of sequencing for each subject (row 2). Values within individual heat
map cells are the percentage representation within that subject.

Four components of the core mycobiome proposed by Ghannoum and colleagues (Glomus,
Teratosphaeria, Saccharomycetales and Dothioraceae) were absent from our high frequency
listing. Several explanations could account for such discrepancies. First, the fungi were simply
not present in the subjects sampled. Second, the identifications were spurious ones. Third, the
taxonomic assignments were made to different levels in the two studies. In our case, sequences
initially assigned to the genus Glomus were found in high abundance, but were eliminated
following primer artifact and DeconSeq filters (Figure 4.1). Although Teratosphaeria was not
detected in any of our subjects, we did have unclassified sequences in the order to which it
belongs, Pleosporales (Figure 4.4). Two of the taxonomic assignments in the study by
Ghannoum et al. were at the higher taxonomic ranks of order (Saccharomycetales) and family
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(Dothioraceae). Saccharomycetales is a large monophyletic order with about 1,000 known
species across many genera 49, several of which were identified in our study. We note that one
member genus in the family Dothioraceae, Sydowia, was a prominent taxon assignment in our
study before being eliminated by early step sequence curation filters (Figure 4.1).
Five genera (frequencies and ranges) were identified in high frequency in our study (Figure 4.3)
but were not part of the basal oral mycobiome proposed by Ghannoum et al.: Malassezia
(100%, 12.98–96.01%), Irpex (100%, 0.02–4.07%), Cytospora/Valsa (100%, 0.005–2.92%),
Lenzites/Trametes (100%, 0.02–1.18%), and Sporobolomyces/Sporidiobolus (100%, 0.01–
12.87%). Malassezia is discussed in the following section; all of the other four genera are
common soil and/or plant pathogens that are widespread in common environmental sources in
temperate zones. Members of three of these genera, Irpex 50, Cytospora/Valsa 51and
Sporobolomyces/Sporidiobolus 48 were previously identified as causative agents in infections in
immune compromised persons. In this context, it seems prudent to consider these taxa worthy
of attention in future studies.
Species of Irpex and Cytospora/Valsa were all identified at less than 1% of sequences and were
found in all subjects. Whether introduced to the oral mycobiome as transients through ingestion
or inhalation, the sensitivity of detection for these genera is particularly important because of
their previous implications as opportunistic human pathogens. Irpex lacteus was identified in the
case of a feverish 9-year-old girl being treated for acute lymphoblastic leukemia50. Valsa sordida
was isolated from a 55 year old woman suffering sinusitis due to complications with treatment of
acute myeloid leukemia51. While both were administered amphotericin B, an antifungal, only the
former was successfully treated. The latter died two weeks after the antifungal was first given. In
both cases, environmental strains of these fungi do not proliferate at temperatures above 30
°C50,51. The adaptability of Irpex and Cytospora/Valsa to increase maximum growth
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temperatures to 37 °C illustrates their future potential in opportunistic mycoses, especially in
instances such as these, where host immunity is compromised by cancer therapies.
Sporobolomyces/Sporidiobolus was represented in four of the six individuals, with 13% of
sequences from one subject classified to these genera. Although considered a rare invasive
pathogen, Sporobolomyces spp. have been identified in several cases. This genus was
detected in a bone marrow biopsy from an AIDS patient and in other cases of cutaneous and
nasal infections52. Its presence at high abundance in one of our subjects suggests that potential
proliferation of Sporobolomyces would not be inhibited in the oral niche, nor is it inherently
dangerous in an immunocompetent individual.

4.4

Malassezia

The most unexpected finding from our study was the presence in all six subjects, at high
abundances from 13% to 96%, of the genus Malassezia (Figure 4.3), one that was not identified
by Ghannoum et al.23. On the experimental side, the results from our negative controls strongly
support the conclusion that Malassezia sequences were not introduced during the processing of
samples. There is additional support from the literature for the argument to include Malassezia,
a recognized commensal and pathogen in humans and other mammals53, as a member of the
basal mycobiome. Well known to cause a variety of skin disorders54, Malassezia was recently
identified by metagenomic sequencing as associated with scalp disorders such as dandruff 55.
More directly relevant to the oral cavity, one of the main entryways for microbes into the
airways, Malassezia was also discovered by metagenomic sequencing in the sputum of cystic
fibrosis patients19. The mouth is the point of entry into the gastrointestinal tract, and Malassezia
was identified by culture-independent, Sanger sequencing of cloned 18S amplicons from human
stool24. Directly relevant to the mammalian oral cavity, Malassezia species were shown to
occupy the mouth of dogs56 and underwent zoonotic transfer by health care professionals from
their dogs to neonates where they were responsible for serious infections57. Since the four more
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recent and culture-independent metagenomic studies that identified Malassezia in human
biocompartments used subjects from worldwide geographies, different protocols for molecular
biology, and different rules for sequence and taxon curation, the consensus on this genus was
compelling evidence for its inclusion as a legitimate member of the basal oral mycobiome. It is
noteworthy that each of the metagenomic studies reporting Malassezia, including ours,
employed relatively harsh extraction protocols that were more likely to recover Malassezia DNA
since species in this genus are known to have especially thick cell walls. The relatively harsh
bead breaking step we employed did not appear to unfavorably impact recovery of other
salivary genera given the agreement between our study and the prior report on the salivary
mycobiome23.
Additional characteristics of Malassezia species53, have probably contributed to the previous
failures to recognize Malassezia as a prominent oral commensal. First, culture-based methods
may not have captured Malassezia species since most have growth requirements for lipids and
require specialized culture media 58. Second, the taxonomy and nomenclature issues also
complicated studies of Malassezia, which are dimorphic fungi (yeast and mycelial phases) that
have been placed in multiple genera. Although much of the taxonomy within the genus has
been sorted out, studies undertaken before the mid-1990s and those without knowledge of the
recent resolutions of nomenclature may have missed this genus.

4.5

Unclassified sequences

Only 1.6% of total sequences were deemed “unclassified fungi”, of which 57% were classified to
family-level or above. Additional steps were taken to improve the representation of unclassified
fungi by identifying the reference sequences to which they were matched and submitting those
reference sequences (typically longer sequences containing 18S, ITS1, 5.8S, ITS2, and 28S)
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Figure 4.4: Distribution of unclassified sequences at all taxonomic levels
above genus for six healthy subjects
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back to Genbank to see if more specific taxonomies would emerge. Resolved taxonomies were
accepted if sequence alignments matched a sequence with ≥90 sequence coverage and ≥99%
alignment identity, following strict recommendations59. Of all unresolved sequences, references
matched to a more specific taxonomy than their original designations for ~60% of unclassified
accession numbers identified. Measures were taken to redefine relative abundance data for the
sequences affected. More often than not, we found that the resolved taxonomies were already
present in the dataset, and we were able to remove unclassified designations, while boosting
the numbers of a genus that was already identified. Cladosporium was one of the most strongly
affected genera, whereby resolved counts could often exceed the number that were reported by
our standard pipeline.

4.6

Concluding remarks

Herein we have assessed our pipeline using a deep sequenced dataset of ITS1 sequences from
the saliva of 6 healthy subjects. We showed that each step creates an improved curated dataset
with greater legitimate representation of fungi at the genus level. Contributions toward
examining sequences classified more broadly than the genus level also improved the
representation of legitimate sequence matches, decreasing the percentage of unclassified
sequences compared to the study by Ghannoum and colleagues. We provided supporting
evidence for new members of the oral community and confirmed the presence of those already
known.
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Chapter 5. Variation in healthy subjects
5.1

Introduction

The goal of this chapter is to demonstrate how healthy individuals vary in their oral mycobial
profile between subjects and over the course of two weeks within a subject. This information will
help us account for natural variation when considering results of a time course study for
chemotherapy patients. First, we used healthy subjects to determine minimum sequencing effort
required for capturing the majority of diversity in a sample, so that minor, but reproducible
components are not overlooked. This was accomplished by generating theoretical rarefaction
curves and conducting an empirical evaluation of the effect of sequencing depth on genus
recovery. Second, we assessed for subject mycoprofiles that could be partitioned by mycobial
content and prevalence. Grouping subjects is especially important for comparing trends in
patients with similar profiles that are affected by disease states. Third, we examined the stability
of mycoprofiles over a two time point (day 1, day 14) longitudinal study. Our hypothesis was
that, in the absence of changes in subject lifestyle activities, the mycoprofile will stay essentially
the same over 14 days. Saliva samples were given designations to denote the cohort to which
they belong, the subject, and the time point (Figure 5.1).

Figure 5.1: Breakdown of sample notation for oral mucositis study.

2-001-3
Arm #
1 (healthy)
2 (naïve chemo)
3 (non-naïve chemo)

Subject #
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Time point #
1 (Day 0)
2 (Day 2)
3 (Day 9)
4 (Day 14)

5.2

Minimum sequencing effort for saliva samples

Since samples vary in sequencing efficacy, it is useful to determine the minimum sequencing
effort required to capture inherent fungal diversity. Of the 30 arm 1-healthy subjects, 24 were
adequate for DNA sequencing and analysis. Four subjects not suitable for sequencing were as
follows. Subjects 1-4 and 15 yielded NanoDrop readings that were similar to values obtained for
reagent blanks (Section 3.5) and were unable to be amplified. Subject 9 was not processed
because no saliva remained after bacterial sequencing. Subject 22 was only successful in
amplification and sequencing of the first time point. This left 47 time points to represent the
remaining 24 subjects. After applying our pipeline, 480,121 sequences were retained with an
average of 10,215 sequences per sample. However, some samples were represented by only a
few hundred sequences. While some studies suggest as few as 40 sequences are needed to
categorize a sample60, our negative controls revealed non-legitimate, but high quality
sequences that pass through the pipeline in low amounts (Chapter 3). Such spurious sequences
likely misconstrue the diversity of a sample, especially when sequencing effort is low.

5.2.1 Rarefaction curves
In order to determine the minimum amount of sequences required to capture the majority of the
diversity in an oral sample, rarefaction curves were generated using an implementation of R in
VAMPS. Ten iterations were performed for each of the 47 samples and average values were
plotted to visualize a shared minimum sequence value where the curve reaches an asymptote
(Figure 5.1 panels A-X: blue and orange). The point at which the curves commonly plateau is
the required sequencing effort for oral samples to be confidently analyzed here and in future
studies. Many of the curves never reached asymptote, including samples with some of the
greatest sequencing efforts (time point 4 for subject 18 and 14 with 39,201 and 30,637
sequences respectively). This was likely due to occurrences of taxa in lower abundances that
inflated the slope of the curve.
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Figure 5.2: Panels A-X: Average of 10 rarefaction curves generated for arm 1-healthy
subjects time points 1 (blue) and 4 (orange) with all genera and for time points 1 (gray)
and 4 (yellow) after removal of genera with relative abundance < 0.1%.
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Where Ghannoum et al. eliminated taxa appearing at less than 1% of sample abundance, we
predicted that by removing even fewer taxa (< 0.1% relative abundance), we could reach
asymptote for our samples. At lower sequencing efforts, as in Ghannoum and colleagues’ study
(average 1,702), 1% relative abundance is only ~17 sequences, where eliminating taxa at 1% in
our study meant removing a mycobial component represented by as many as 300+ sequences.
Arguably, discounting such taxa from larger sequencing efforts ignores legitimate contributions
to the oral mycobiome. We hypothesized that excluding less taxa would still eliminate artifactual
singletons and other insignificant taxa, retain rare, but legitimate taxa, but also level off
rarefaction curves, indicating the majority of the diversity had been captured. Singletons and
other low abundance genera have the biggest impact on reaching the asymptote, and these
would be removed with a 0.1% relative abundance cutoff. To test our hypothesis, an additional
ten iterations were performed and averaged for each sample after the removal of taxa at < 0.1%
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relative abundance, which we used as the criterion to define “abundant genera” (Figure 5.1
panels A-X: gray and yellow). For four of the samples there was no change in number of taxa
represented (indicated by asterisks in Table 5.1). Two of these four (Figure 5.2 panel M orange,
panel W blue) reached asymptote despite this, and so did not require such modifications. The
other two came from subject 30, both of which yielded low sequence counts of 395 and 271 and
did not reach asymptote, casting doubt on this low sequencing effort. Another suspicion about
trusting sequence counts as low as these was raised during preliminary analysis; these two time
points had the greatest beta diversity between them of any given subject. For sequencing efforts
as low as this, even a singleton would be greater than 0.1% relative abundance and could also
possibly be a legitimate taxon. It is clear by the rarefaction curve that the majority of the diversity
for subject 30 time point 1 was not captured (Figure 5.2 panel X blue). Both time points for this
subject would be greatly affected by additional sequencing effort; only 132 sequences are
needed for one additional taxon time point 1 and 903 sequences for time point 4. Further
evidence that sequencing effort in the hundreds is inadequate for analysis is seen in Figure 5.3,
where sampling efforts were pooled after inadequate sampling effort.
Nearly all of the remaining 43 samples reached a clear asymptote when taxa < 0.1% were
removed, and certainly the majority of diversity had been captured (Table 5.1). Most notable
was how drastically rarefaction curves were impacted after this modification, with an average of
69.2% of taxa retained, while sequence counts remained relatively unchanged at an average of
99.6% retained. Therefore we addressed our hypothesis and showed that by removing fewer
taxa (< 0.1% relative abundance) than comparable studies23, we reached asymptote, eliminated
insignificant taxa, and retained rare, but legitimate taxa, while capturing the majority of diversity
in a sample.
The slight modification of eliminating taxa below 0.1% relative abundance allowed us to
determine a minimum recommended sequence threshold. Visual inspection of the curves led us
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Table 5.1: Dataset statistics of arm 1-healthy samples post removal of < 0.1% taxa, Asterisks indicate no taxa were below 0.1%
relative abundance, orange indicates reasonable additional sequencing effort is needed for ≥ 1 taxon (< 6,000 sequences), green
represents < 95% taxa were subsampled

Effort for 90.0%
taxa

5
6
7
8
10
11
12
13
14
16
17
18
19
20
21
22
23
24
25
26
27
28
29*

Effort needed
for ≥1 Taxon

to propose a conservative minimum of 3,000 sequences to achieve a rarefaction plateau for all
samples. Using sample iteration averages, a lower limit of 3,000 sequences yielded an average
of 97.3% taxa subsampled, with only 8 time points subsampling at < 95% of taxa (Table 5.1
green). Analysis of the 8 poorly performing samples follows. Three of these, samples 10-4, 141, and 20-4, all had taxonomic counts between 4 and 9, thus their subsampling percentages
above 90% are essentially 100%. The other 5 reached 95% of subsampled taxa by 3,660
counts, indicating that a sequence count of 3,700 sequences would be adequate to meet at
least this percentage of total taxa.
On its own, sequencing effort at 95% sub-sampling is a misleading metric for some samples
because it only considers taxa that were obtained during experimental sequencing. For
example, based on results from subject 30, already shown to be unreliable due to its inability to
reach asymptote (Figure 5.2, Panel X), only 336 sequences are required to reach 95% of taxa.
However, confidence cannot be had in this value alone, especially when the rarefaction curve
has not plateaued and the effort needed to acquire an additional legitimate taxon is not
unreasonable (>1,000 sequences in the case of sample 30).
In addition to visual inspection, delta values (Δ sequencing effort/Δ sub-sampled taxa) were
calculated between the last two sequencing efforts represented in the rarefaction curves. While
an exact number cannot be inferred, this metric represents an estimate of the additional number
of sequences required to add one taxon to the sample. This value is a minimum estimate, as it
is expected that the slope of the line will continue to approach zero and eventually reach
asymptote past the point of our maximum sequencing effort. The median delta value obtained
for all time points was 1.2E+07 sequences, which is an unreasonable amount of experimental
sequencing required for a negligible gain of only one taxon for the time and labor required. Nine
of the samples levelled off completely (undefined, or infinite, value) and seven of the samples
showed a reasonable effort of sequencing could be made for additional taxa (< 6,000
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sequences). Aside from the two time points from sample 30, time point 24-1 indicated a need of
only 1,611 sequences to acquire an additional taxon, suggesting that a sequencing effort as low
as 1,776 is not adequate to represent the majority of the diversity in this oral sample. These
data suggest that sequencing effort should be greater than 2,000 counts post-pipeline, a less
conservative estimate than the 3,700 we found to necessary to capture the majority if diversity.
While the remaining four samples only require 3,675- 5,359 sequences to gain an additional
taxon, the percentage of subsampled taxa would only decrease to 92.6% at a minimum, with
diminishing returns produced for sequencing efforts beyond this point. Application of a minimum
sequencing effort of 2,000 affected three time points in our healthy dataset. Therefore, time
points 24-1, 30-1, and 30-4 were excluded from further analysis, leaving 44 time points
representing 23 subjects. Two of the arm 1-healthy time points fell between 2,000 and 3,700
sequences, but analysis by their delta and 95% sub-sampling values show that the majority of
diversity had been captured, so they were retained in analysis.
Based on these results, we recommend that a minimum of 3,700 sequences are collected for all
saliva samples to obtain at least 95% of taxa. In future studies, samples with counts below
2,000 should be excluded and for those falling within 2,000-3,700, caution should be taken by
creating supporting material in the form of rarefaction curves, delta values, and subsampling
requirements to reach the majority of taxa at ≥ 0.1% relative abundance.

5.2.2 Empirical measurement of richness as a function of sequencing depth
Due to the imperfect nature of experimental sequencing, our first attempts for particular samples
yielded low sequence counts and required additional sequencing. Ultimately, all replicate
sampling efforts were combined for analysis. Failure in obtaining a large number of sequences
on the first try provided a unique opportunity for empirical evaluation of our required estimate of
3,700 sequences for capturing diversity. Figure 5.3 shows four samples chosen to compare
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Figure 5.3: Experimental richness comparisons of sequencing iterations of four arm 1-healthy samples (as described in Figure
5.1) at multiple sequencing depths using abundant genera (genera ≥ 0.1% relative abundance). Panel A: Bar graph showing
effects on genera representation as sequencing effort increases and on combining all sequences from multiple efforts
(Iterations Totals, rows 4, 9, 14, 18). Red lines separate each sample. Highly represented genera are pink (Malassezia), blue
(Pichia), orange (Cladosporium), salmon (Cryptococcus), and navy blue (Candida). Panel B: Scatterplot of empirical rarefaction
curve showing percentage of total abundant genera from combined efforts (y-axis) found at each sequencing depth (x-axis) for
the four samples.
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experimental richness between sequencing iterations. We found that only 35-55% of abundant
genera from pooled efforts were represented in sequencing attempts comprised of 41-127
sequences. In sequencing efforts this low, missing genera included core members such as
Aspergillus, Aureobasidium, Cladosporium, Epicoccum, Fusarium, Malassezia, Penicillium, and
Saccharomyces. In contrast, iterations with sequences near 2,000 or greater shared at least
94% with pooled abundant genera. In all four instances, increasing sequence counts above
2,000 did not significantly add abundant genera, and pooling unequal attempts had little to no
impact on their overall quantitative representation. Therefore, 3,700 is a sound estimate for
required sequencing effort, and as little as 2,000 sequences are needed for capturing the
majority of diversity. These results also suggest that the mycoprofile of a sample can be
determined with sequences counts in the tens to hundreds, but the ability to capture
representation of opportunistic pathogens and even core members in lower abundance is lost.
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5.3

Healthy subjects partition into distinct mycoprofiles

We asked the question of whether healthy subjects could be grouped by similarities in their
mycobial content (mycoprofiles), determined by frequent prevalence of specific genera. The
Morisita Horn metric was chosen for comparing arm 1-healthy samples’ beta diversity
(differences between samples), as it is not strongly affected by differences in sequencing effort
across time points. Samples were clustered in a dendrogram using VAMPS’s R Vegan tree and
pie charts were placed to visually explain clusters by taxonomic representation (Figure 5.4).
Designations to mycoprofiles were made based on relative abundances of the most prevalent
genus; the requirements for placement into a mycoprofile groups were 1) prevalent genus had
to be >40%, and 2) no other genus could be >25%. Two main groups were visualized in the
dendrogram, with the largest of the groups predominated by Malassezia in amounts from 4295%. The second group is predominated by Candida species (excluding Pichia) at 60-100%.
There were no other genera that met qualifications to constitute a mycoprofile, so the rest of the
samples were deemed the “Diverse mycoprofile”. This third group often contains Malassezia,
but little to no Candida.
Next, we asked whether these mycoprofiles were stable. Of the 21 subjects which had an
additional time point, 13 of them were in the same group or “mycoprofile”, after a period of 2
weeks. Only 3 of the 9 subjects with Malassezia mycoprofiles stayed in this type, with 6 meeting
qualifications for the Diverse mycoprofile after 2 weeks and 5 of these retaining Malassezia as a
prevalent component. In contrast, only 2 of the 8 patients with Candida mycoprofiles for at least
one time point met qualifications for the diverse mycoprofile group within two weeks. This
suggests that Malassezia mycoprofiles are more fluid in their diversity over time, while Candida
mycoprofiles are more stable. Furthermore, a plot of beta diversities in a heat map show two
blue groups representing the Malassezia and Candida mycoprofiles, as well as a red group of
sequences that do not resemble each other or any other profiles, representing the Diverse
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Figure 5.4: R Dendrogram of arm 1-healthy
genera relative abundances ≥ 0.1% using
Morisita-Horn distance metric. Taxonomy pie
charts of genera are ordered by dendrogram
position. Colored backgrounds indicate
mycoprofile type with light gray representing
Candida, white representing Malassezia, and dark
gray representing Diverse, described in 5.2

Figure 5.5: Heat map of arm 1-healthy time points showing mycoprofile group
remains relatively consistent after a two week period using Morisita-Horn distances
(upper right, above gray boxes) and Bray-Curtis distances (bottom left triangle,
below gray boxes). Samples were ordered by subject and mycoprofile, where
mycoprofile for a subject was determined by at least one time point belonging to a
Malassezia or Candida mycoprofile, described in 5.2. Subjects were grouped:
Malassezia- 5, 6, 16, 17, 19, 21, 22, 26, 28, and 29; Diverse- 8, 12, 13, 23, and 24;
and Candida- 27, 7, 10, 11, 14, 18, 20, and 25. Bottom left inset shows MorisitaHorn distances for samples ordered according to figure 5.4 dendrogram.
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mycoprofile (Figure 5.5 inset). This confirms the groupings suggested by the dendrogram are
driven primarily by Malassezia and Candida content. Ordering the heat map by subject number
(including time points 1 and 4) shows similar groupings to the inset and suggests that
mycoprofiles typically constitute the same genera over time.

5.4

Conclusions

In this chapter we explored the healthy fungal mycobiome of 23 patients in order to determine
how healthy individuals vary in their oral mycobial profile inter- and intra-subject. We supported
our hypothesis that removing taxa at less than 0.1% sequence abundance would eliminate
artifactual taxa and retain rare but legitimate taxa. Using the rarefaction curves and empirical
evaluation of iterations we determined the minimum sequencing depth needed for capturing
95% of genera richness. We found that approximately 2,000 would suffice for most samples, but
3,700 sequences were required to capture richness for all samples. We recommend collecting
3,700 ITS1 sequences for oral mycobial samples for future studies. To our knowledge, this is
the first study to determine such an estimate for metagenomic analysis of fungi. We also
discovered that there are typically 3 mycoprofiles that represent healthy subjects and ~60% of
individuals stay within their original mycoprofile after a period of two weeks. Of the Candida and
Malassezia mycoprofiles, we found the Malassezia mycoprofile to be the least stable. This
implies that Malassezia types may be more susceptible to change due to transient
microorganisms. It also implies that individuals with Candida mycoprofiles will remain relatively
stable. With Candida sp. known to be opportunistic pathogens, this suggests that those
harboring Candida in a healthy state may be more vulnerable during states of decreased
immunity than individuals with Diverse or Malassezia mycoprofiles.
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Chapter 6. Fungi in oral mucositis
6.1

Introduction

After our development of a robust protocol and new knowledge that healthy subject
mycoprofiles remain relatively constant over time, we were able to explore fungi as they relate
to disease. For this study we focused on oral mucositis, a side effect of chemotherapy in which
fungi have previously been implicated. We predicted that mycoprofiles appearing mostly as
Candida at day 0 would be considered the least healthy and would be those most susceptible to
oral mucositis during chemotherapy, as Candida spp. are the most common cause of infections
in cancer patients61. While the Candida mycoprofile has only been identified in approximately
one-third of all healthy subjects studied in our lab for this project and others, a community
predominated by C. albicans species from the start, has natural potential for opportunistic
infections. We predicted that those with the majority of taxa represented by Malassezia and
other core members would be the least likely to develop oral mucositis and candidiasis, as
Malassezia (and some other genera) potentially compete for space and resources with Candida
to maintain a healthier equilibrium. The goals of this chapter are twofold: First, to evaluate
trends in community membership as oral mucositis develops and progresses for each subject
using standard WHO (World Health Organization) scores. Second, to explore general changes
within individuals between communities at day 0, day 2, day 9, and day 14 time points.

6.2

Mycoprofiles of cancer patients

Forty-nine cancer patients participated and 40 completed the study with all four time points and
enough remaining saliva for fungal ITS1 sequencing. Figure 6.1 shows genera distributions for
all sequenced time points of 46 patients, representing 1,411,136 sequences. All three of the
mycoprofiles previously recognized in healthy subjects, Candida, Malassezia, and Diverse, are
also in evidence in the cancer patients. Only 21 of these subjects produced sequences at all
four time points due to the unpredictable nature of clinical samples; it is possible that many
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Figure 6.1: Bar graphs
of all sequences
obtained for cancer
chemotherapy patients
arms 2-naïve chemo
(panel A) and 3-non
naïve chemo (panel B).
Mycoprofiles are
visualized by
distributions of colored
bars. Malassezia
mycoprofiles are
predominantly pink and
Candida mycoprofiles
are predominantly navy
blue.

A
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samples did not contain enough fungi to provide adequate template for PCR and sequencing.
Moreover, our methods likely exacerbated this by additional loss of PCR product when
removing primer dimer artifacts. Seventeen of these 21 patients met the minimum number of
required sequences (explained in section 4.2) for all time points.
Of these 17 subjects, 11 came from the arm 2-naïve chemo cohort and 6 came from the arm 3non-naïve chemo cohort (recurring cancer patients). The average sequencing effort per time
point for these 17 subjects was 11,118 (range 2,009-37,355), coverages that were more than
adequate, as discussed in the preceding chapter. Eleven additional patients outside of the
complete 21 were successfully sequenced with adequate depth for at least two time points and
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could provide useful information for future analyses about specific time points. Over 75% of
subjects stayed within their original genus mycoprofile during the entire course of treatment,
even more than the 60% for healthy subjects (Chapter 5).
Because we had determined that mycoprofiles were relatively stable in healthy subjects, we
understood the importance of determining the mycoprofile composition at the day 0 time point.
We asked the question of whether mycoprofile type and frequency in the cancer cohort would
differ from the three mycoprofiles identified in healthy subjects. Both the Malassezia mycoprofile
and Candida mycoprofile were present, but at altered frequencies, and a new profile emerged
as well, containing mostly Aureobasidium (Figure 6.2). Not a single one of the patients started
with the Diverse mycoprofile, though one (subject 2-001), had a more diverse Malassezia
mycoprofile than the other subjects with the Malassezia type. The absence of a Diverse
mycoprofile in the cancer patients is interesting because 57% of the healthy cohort showed
Diverse mycoprofiles for at least one of the two time points. Greater than 75% of the cancer
subjects had Candida mycoprofiles at Day 0, while only 38% of healthy subjects showed a
Candida mycoprofile. A different study on 33 additional healthy subjects performed in our lab
also places the number of Candida mycoprofiles at a yet lower frequency (24% with > 50%
Candida albicans, and 3% with greater than 75%, Linda Strausbaugh, personal communication)
than observed for our chemotherapy cohort. One explanation we propose is that differing
frequencies could be due to the difference in average in age between the two groups (48.1
years for the healthy subjects sequenced vs 60 years for the 17 cancer subjects in question).
This supports published evidence that oral carriage of Candida spp. is more apparent in
individuals who are in advanced age groups (74.2% for ages 71-92, and 35.0% for ages 5670)62. However, there was only a slight difference in the average age for chemotherapy subjects
with Malassezia mycoprofiles at day 0 (58 years) and the average for Candida mycoprofile
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subjects (59.6 years). We interpret this to mean that there is no age-related influence on the
ability of an individual to carry oral Malassezia.
One contributing factor to the worldwide rise in groups of individuals with lowered immune
function is the increase in life expectancy for the human population. Urine proteomes revealed
19 proteins that are differentially expressed in younger age groups (19-26 and 45-54 years)
compared to older ages (72-90 years), many of which were involved in tissue remodeling and
increased immune dysregulation63. As the most common oral pathogens are Candida spp., and
fungal infections predominate in individuals with lowered immune function, increased frequency

Figure 6.2: Dendrogram and corresponding pie charts for abundant genera (≥ 0.1% relative
abundance) observed at day 0 time points for arms 3- naïve chemo and arm 3-non-naïve
chemo patients for which the complete longitudinal dataset was available. Mycoprofiles are
visualized by Malassezia (pink), Aureobasidium (mauve), and Candida (navy blue).
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of Candida mycoprofiles in older groups in our study may also be due to an age–related decline
in immunity.
Among this cohort, age is not the only explanation for decline immunity. We propose that a
differential representation of Candida mycoprofiles for chemo arms may also be due to immunecompromised immune systems caused by the cancer itself. Another study reports that in mice,
during early stages of tumor growth, a rise in H2O2 and TNF-α levels were detected, but after
progression of the tumor, the effectiveness of macrophage activity decreased against C.
albicans64. Between arm 2-naïve chemo and 3-non-naïve chemo cohorts, none of the arm 3
participants displayed Malassezia mycoprofiles. It is possible that merely the state of having
cancer, or having prior chemotherapy, contributes to a perpetual state of susceptibility to
opportunistic infections. The sole Aureobasidium mycoprofile came from an arm 3 subject, and
was the first we encountered of its kind.

6.3

Candida mycoprofile

To make associations between changes in community membership during disease states, it is
often beneficial to group like types of patients; in small studies such as this one, this strategy
might better reveal co-occurrence of mycobiome features and produce similar disease
phenotypes. Thus, we grouped the 13 subjects according to mycoprofile. The thirteen subjects
that had Candida mycoprofiles at day 0 were compared to the rest of the time points within that
subject, and also across subjects using the Morisita-Horn distance metric as a beta-diversity
estimator (Figure 6.3). In general, there were no differences at the genus level either within a
Candida mycoprofile subject over the course of the four time points or between cancer patients
at the majority of time points. Three time points from the patient cohort had mycoprofiles that
were atypical in that they displayed high contributions (>5%) of genera other than Candida (2029-3, 2-005-3, and 2-031-4, with the first being the most different of any time point). Time point
2-029-3 was characterized by the largest beta diversity distance from any other sample with
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high levels of Saccharomyces (28.5%), Aspergillus (10.4%), and Penicillium (6.7%). Time point
2-005-3 showed the next greatest beta diversity distances and was characterized by
Cladosporium (17.4%) and Trichosporon (7.9%).Time point 2-031-4 exhibited high levels of
Malassezia (17.5%) and Aureobasidium (9.3%). These non-Candida genera are common
mycobial components found in healthy subjects27. All other 49 time points had no genera other
than Candida with a contribution of more than 5% abundance. This suggests that genera
components in cancer patients with Candida mycoprofiles can be expected to remain relatively
unchanged from their baseline community membership.
WHO scores were used to measure the severity of oral mucositis, which range from 0-4, where
0 is no change in oral health, 1 is soreness or erythema (reddening) of mucosa, 2 is erythema
and ulcers with the ability to eat solid foods, 3 is ulcers and the necessity of a liquid diet, and 4
is necessity of a feeding tube as alimentation is not possible65. Nine of the thirteen patients
experienced OM at a WHO score of 2 at any given time point (2-005, 2-007, 2-020, 2-025, 2029, 2-031, 3-006, 3-014, 3-015). Two subjects acquired WHO grade 1 OM (3-001 and 3-005),
and two subjects were unaffected by oral mucositis (2-012 and 2-016). At the genus level there
were no obvious mycoprofile differences separating these subjects.
While the Candida genus level mycoprofiles did not demonstrate informative changes during
chemotherapy, they did display an important day 0 association to candidiasis. Of the 7 patients
who acquired candidiasis, all of them had original day 0 communities comprised mostly of
Candida. Due to non-broad spectrum effects of antifungals, species level analysis is particularly
important for the biomedical community and for evaluating trends in subject populations. Day 0
relative abundances at the species level, is primarily comprised of albicans (medium blue 14.399.9%) and dubliniensis (gray 0- 79.6%). Four groups emerged out of these 7 subjects (Figure
6.4). The first group (subjects 2-005 and 2-029) started out almost entirely as C. albicans, which
became the source of infection at time point 2 in both subjects. By time point 3, the infection had
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cleared and albicans was replaced with many other non-Candida and non-Malassezia species.
At time point 4, C. albicans began to increase again, but there was no recurrence of infection.
The second candidiasis group that emerged (subject 2-020 and 3-001) showed a species
majority of C. dublienensis (79.6- 57.9%) with the rest occupied by C. albicans, at time point 0.
However, by time point 2, C. albicans counts increased by an average of 10%, and an additional
average of 40% by time point 3. For both patients in this group, infection persisted from time
point 2 through time point 4, and C. albicans remained above Day 0 abundance thresholds. The
third candidiasis type was made up by a single subject (2-007) and similar to the second group,
sequence counts primarily consisted of C. dubliniensis. However, this group contained a small
percentage (8.2%) of C. glabrata, which grew to 46.8% by time point 3, potentially being the
cause of candidiasis for this subject rather than the typical C. albicans. C. glabrata has been
shown to colonize approximately 5% of cancer patients in a review of three studies15. The fourth
group (subjects 3-005 and 2-011) appeared to have strong C. albicans representation
throughout all time points where data was obtained, but only exhibited candidiasis at time point
3. In all cases we note that the pathogen implicated in infection was present at day 0 and that it
remained detectable after infection had resolved. As this is a small subset of individuals, a
larger study is required to determine if these groupings represent all possible types.
Antifungal drugs were administered to patients in this study who acquired infections. Six of the
seven subjects presented here were prescribed Nystatin, while only subject 2-007 was
prescribed fluconazole. It is presumed that the physicians did not test for Candida species
before prescribing these drugs because fluconazole has lower effectiveness against C. glabrata,
which is the main source of ITS1 sequences for subject 2-007.
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Figure 6.3: Heat map and genera distribution through all time points of patients with day 0
Candida mycoprofiles from arm 2-naïve chemo and 3-non-naïve chemo cohorts. MorisitaHorn metrics were used to generate the heat map. Abundant genera (≥ 0.1% relative
abundance) were used to generate bar graphs, with navy blue representing Candida.
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Figure 6.4: Species distributions of patients (time points 1-4) who develop candidiasis during
the course of chemotherapy fall into four categories: A- Candida albicans predominates at
baseline and during infection at time point 2, with reduction of C. albicans at time point 3 and
an increase at time point 4. B- Candida dubliniensis predominates at baseline and then
decreases as predominance of C. albicans increases with infection at time points 2-4. CCandida dubliniensis predominates at baseline and C. glabrata prevalence dominates by
time point 3 with infection, as well as into time point 4. D. C. albicans prevalence dominates
throughout time points 1-4, with infection only occurring at time point 3. Red asterisks
indicate time points where patients show candidiasis. Purple stars in key indicate
predominant Candida species from pie charts.

6.4

Malassezia mycoprofile

Of the 3 subjects with day 0 Malassezia mycoprofiles, all stayed within their relative type over
the course of chemotherapy, with the exception of subject 2-001, who originally showed a more
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diverse Malassezia mycoprofile than the other two subjects, and included 27% Candida as well
as 49% Malassezia. For the duration of the study, subject 2-001 showed Candida proportions
ranging from 8-40% and Malassezia proportions from 9%-70% (Figure 6.5).
This subject also was affected by the worst grade of OM of the three samples with a WHO score
of 2 at time point 3. Though N is limited for this dataset, subject 2-035 kept a consistent WHO
score of 0, while subject 2-004 only developed OM at a WHO grade of 1 at time point 3. One
reason might be that Malassezia can exert an ameliorating effect such that a Malassezia
mycoprofile with little presence of Candida may be less affected by OM. Another reason that
this subject may have been more strongly affected by OM at time point 3 was that his oral
mycobial profile is most different from its baseline state at this time point. Alternatively, as an
effect of developing OM, his mycobial profile is most altered at this point. While it appears that
healthy mycobial states allow a wide range of Candida membership (up to 100%), the relative
abundances of this genus in healthy subjects do not typically change within the period of two
weeks. Major deviations from the baseline profile may be indicators that the subject is
experiencing OM.
None of the Malassezia mycoprofile patients acquired infections, which is interesting because
Malassezia has been shown to be an opportunistic infectious agent on skin of a wide variety of
mammals. Malassezia is a genus that can be resolved at the species level with ITS1, and we
found that the majority of Malassezia sequences were represented by the species restricta and
globosa, with some profiles containing sympodialis, in all arms 1-3, whether healthy or chemo.
Our results were concordant at the species level with other human samples where Malassezia
has been found scalp, stool, skin, and sputum 55,24,66,19. The skin and the mouth are very
different biocompartments with radically different surface characteristics, so Malassezia may not
have evolved to cause infections in the oral cavity, even though this fungi is well acclimated to
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Figure 6.5: Heat map and genera
distributions for arm 2-naïve
chemo and 3-non-naïve chemo
patients with Malassezia
mycoprofiles
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growth at human body temperatures. If this is true, Malassezia may act as a viable competitor
for resources against species of Candida that do cause infections, providing a type of protection
against Candida, and perhaps other pathogens.

6.5

Diverse mycoprofile/Aureobasidium mycoprofile

In this group of subjects, only one mycoprofile belonged to a type outside of the Candida and
Malassezia mycoprofiles. However, instead of being characterized by a diverse community of
fungi, the majority of membership was composed of the genus Aureobasidium at 95% relative
abundance. Aureobasidium is found ubiquitously in the environment, and is only considered to
be pathogenic when isolated from immunocompromised patients67. However, ongoing exposure
to this environmental fungus may influence mycoprofiles. Testing of air samples in the patient’s
home in addition to saliva from their cohabitors could provide support for Aureobasidium origin
from environmental sources unrelated to cancer, such as household dust. Figure 6.6 shows a
heat map of the four time points collected for the single patient with an Aureobasidium
mycoprofile and the distribution of fungal species at each time point. This subject was affected
by OM at a WHO scale of 1 at time point 2 and a WHO scale of 2 at time points 3 and 4.
Aureobasidium levels decreased at time point 2, making way for a larger presence of
Malassezia and the appearance of Aspergillus, the latter of which is a common cause of fungal
infections.

6.6

Conclusions

Here we investigated the effects of cancer chemotherapy on the oral mycoprofiles of 17
subjects by assessing for changes in genera representation over time. We found that there is a
large increase in patients with Candida mycoprofiles in cancer as opposed to in health and that
only subjects with day 0 Candida mycoprofiles developed infections during chemotherapy, likely
due to this genus’s implications of becoming pathogenic in immune compromised
individuals68,69. We discovered little to no change in mycoprofiles during the course of
87

Figure 6.6: Heat map and
distribution of fungal communities
from an arm 3-non-naïve chemo
subject with an Aureobasidium
mycoprofile
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chemotherapy at the genus level. Albeit using a small number of subjects, we revealed that
patterns and changes begin to emerge at the species level in patients who develop candidiasis.
Patients with Malassezia mycoprofiles at day 0 never developed infection, suggesting that
starting with a Malassezia mycoprofile may lead to a healthier experience during chemotherapy.
We report the first case of an Aureobasidium mycoprofile in a cancer patient in a survey study of
metagenomic sequencing of ITS1. This mycoprofile presents a potential susceptibility for
developing non-Candida infection67.
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Chapter 7. Discussion and Future Directions
7.1

Summary

While bacterial microbiome projects have been developed for high-throughput sequencing and
analysis for the last decade, fungal metagenomic studies, specifically in human niches, have
infrequently been attempted. A July 2015 Google Scholar search of “bacterial identification with
16S rRNA” yields 218,000 all-time hits and 11,500 hits for 2015. Whereas a search for “fungal
identification with 18S rRNA” yields 31,800 all-time hits and 2,160 hits for 2015. Even with all of
the caveats of literature searches, this difference is vast and likely reflects truths about the
difficulties of working with fungi. If less than 20% of microbiome studies are investigating fungal
communities, it is no wonder that reliable tools and databases for bacterial sequence
assignments are much more advanced than for fungi. Assigning fungi to taxa is daunting due to
names based on phenotype, redundancies in nomenclature, and lack of type specimens to
validate user-deposited sequences in databases59. This study is the first that attempts to
remedy such challenges with a biomedically relevant patient cohort, by using a curated
database and manually adjusting the dataset by removing poorly aligning sequences, collapsing
redundant genera, and rectifying unclassified sequences to the most reliable sequence match.
The impact of our pipeline greatly simplifies the representation of taxa by eliminating members
that were likely spurious and as a result, places greater emphasis on legitimate community
members and potential pathogens.

7.2

Improvements to sequence generation and analysis

Because fungal analysis is still an evolving process, it is an ongoing necessity to re-evaluate the
data that has been collected against updated databases. Upon bioinformatics reprocessing, at
least some sequences with poor alignment to FMP references may match new fungal entries
and can then be added back to the curated dataset with high confidence. In the future, at the
same time that FMP is re-queried, it would be useful to compare results to other databases that
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have become more fully developed since the start of this project. For example, the UNITE
database has expanded and now redesignates “uncultured fungus” sequences, to more specific
taxonomy where representative sequences provided this information70. The newly formed
RefSeq database also would be useful for confirming accurate assignments against verified
type specimens and for confirming accurate fungal nomenclature resolution59.
The evolutionary age of fungi has allowed for vast differences in species and even strains within
a genus. However, non-resolvable species are still apparent. Future studies should take this into
account not only when assigning taxonomy to ITS1 fragments, but also in the experimental
design phase. As it stands, ITS1 is shown to have a better overall rate of species identification
than ITS2, but this is not the case for all genera. For example, 73% success identifications to
fungal sequences were made using ITS1 vs 69% success with ITS2 across 5,407 species of
Ascomycetes, but the genus Alternaria, one of the members we identified in the core
mycobiome, includes species that are statistically identified with greater accuracy using ITS271.
Other regions for fungal identification have been used that may provide further resolution: large
and small rRNA subunits (28S, 18S), translation elongation factor EF1-α, β-tubulin, actin, and
RNA polymerase II subunits. Ribosomal genes are the most commonly used fungal identifiers,
and so make up a majority of the sequences in fungal databases. The next most commonly
used is EF1-α, though it still comprises a relatively small amount of fungal sequences in
mycobial databases72. If different gene fragments are to be used in sequencing, the
discontinuation and expense of support for 454 pyrosequencing must be considered.
Sequencing costs associated with the Illumina platform have been reported as 75% lower than
those for 45473. Now that we have provided a baseline framework for expectations in community
membership with long reads in 454, comparisons using shorter fragments with Illumina can be
made to validate its performance against our ITS1 genera distributions. Although large and
small subunit genus level identification accuracies were only 60-75% for Illumina-sized
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fragments (compared to ~80% for 454-sized fragments)74, advances in small fragment mate pair
sequencing on the Illumina platform could be adequate for such continuing studies.
While we propose many adjustments and modifications to protocols, there are still many
limitations to be considered as part of fungal metagenomics studies. We can never be sure that
we are capturing all legitimate sequences. Fungi at minimal levels may never amplify in PCR. In
addition, this is still a semi-quantitative approach as the number of ITS1 copies per genome has
not been taken into account. We are also limited by the databases available, and so unknown
fungi cannot be identified until more medically relevant fungi have been cloned and sequenced.
Resolution of nomenclature also continues to provide challenges. With database names based
on their submitter preferences, it still requires hand curation to collapse redundant genera.
Another issue is that there are still subjective steps in library preparation due to the
unpredictable nature of clinical samples. It can be difficult to retain uniformity across samples to
ensure that they are comparable. All in all fungal sequencing and identification is an evolving
process.

7.3

Candida and Malassezia as oral community members

This is the first metagenomic attempt to deeply sequence the core mycobiome of saliva and
offer a minimum sequencing effort to capture the majority of species richness in this niche.
While our community membership was generally in concordance with other studies23, mycobial
datasets were carefully curated to give the most accurate representation of fungal profiles, given
the current status of ITS1 databases. We have also illuminated a genus that was not previously
known to be a commensal of the oral cavity: Malassezia. While Candida sp. have been
extensively studied and are well-known as oral colonizers, little is known about Malassezia
species due to their complicating factors in DNA isolation, special lipid requirements in culturing
and growth rate of hyphae in vitro.
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As the most abundant novel member of the oral community, Malassezia was represented by
47% of all sequences in our deep sequencing analysis of 6 healthy subjects. Malassezia spp.
have been identified as human pathogens, causing pityriasis versicolor, seborrheic dermatitis,
and dandruff53. Malassezia has also been identified in healthy human biocompartments in four
other culture-independent molecular surveys: scalp55, skin66 , airways19, and gastrointestinal
tract24. Malassezia species are known to have especially thick cell walls (~0.12 µm)53 that may
well have contributed to Ghannoum’s inability to recover Malassezia DNA. It is noteworthy that
each of the aforementioned studies that detected Malassezia employed relatively harsh
extraction protocols. With culturing methods, Malassezia has now been confirmed as a common
isolate from healthy oral samples (Patricia Diaz, personal communication). Based on its
predominance, Malassezia is likely an important oral commensal.
We found the representation of Malassezia and Candida to be inverse in nature, resembling an
antagonistic relationship between the two genera. Potentially, both genera compete for the
same carbon source, dextrose75, while Malassezia requires additional lipids for growth. Both
fungi have evolved to withstand human body temperatures while retaining the ability to switch
between yeast and hyphal forms. This gives them the propensity to occupy various niches that
allow one form or the other to propagate and to out-colonize other fungal types. Malassezia
globosa, one of the two common Malassezia species we found in saliva, is normally found as
nonpathogenic yeast on surface layers of skin, but has been shown to form hyphae that extend
into deeper layers of skin to spread yeast into multiple areas76. Several questions remain to be
answered on the importance of finding Malassezia in the oral cavity: Are Malassezia and
Candida equilibrium maintained by host factors? Does host genotype predispose toward a
Malassezia vs Candida mycoprofile? Do external factors, such as season, exposure to
antifungals, and bacterial community composition have an effect on the balance of these
genera?
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Additionally, future studies should include quantitative efforts to assess changes in fungal load
in interesting species such as Candida albicans, Candida glabrata, Malassezia restricta,
Malassezia globosa, Aureobasidium pullulans, and Cryptococcus neoformans at all time points.
Patients that developed candidiasis always started with Candida mycoprofiles, but from relative
abundance data it is unclear whether in some subjects whether Candida load increased to
contribute to infection, as the profile remains stable for the duration of the two weeks. Knowing
whether or not there was an increase in fungal load of certain species could provide more
information on whether species are transients or occupiers that are indeed contributing to oral
mucositis and its complications. The data here is normalized to 100%, but basic gel results
show that not all amplifications are created equal. Some samples, even within a subject,
produce very faint ITS1 bands, while others produce very bright signals. Measuring fungal loads
would be difficult because they require knowledge of ITS1 copy numbers as well as the ploidy of
species that become pathogenic. Classical microscopic staining and identification could be
implemented to assist in this approach for species of interest. To provide information beyond
presence and absence of community members, sequencing beyond the rDNA region could
provide further information about pathogenicity during the development of oral mucositis. Fungal
transcripts could be sequenced to compare changes in gene expression during the disease
state, since ITS1 does not necessarily provide information on if a commensal has become
pathogenic. It would be interesting to see if virulence factors are more highly expressed during
stages of oral mucositis even if the mycoprofile remains relatively stable. Combined with fungal
load information, powerful evidence for contributors to disease would be certain to surface.
Future projects should consider more sophisticated analyses for trends in minor components.
As it stands there is no clear indication of consistent community membership in the Diverse
mycoprofile group and the beta diversity measurements between two time points from the same
subject is very high. The non-predictive longitudinal nature of healthy subjects in this group
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currently inhibits insight into changes that may occur due to disease state. Potentially the
sequences gathered here could be used to combine taxa at the family, order, or class levels to
see if this contributes any clarity to such inconsistencies between time points of a subject,
further defining mycoprofiles that may be more predictable longitudinally.

7.4

Candida and the immune system

In this study we provided evidence that there is an increase in the frequency of Candida
mycoprofiles among individuals with cancer (35% in healthy subject vs >75% in chemotherapy
cohorts). Lowered immune functionality and increased frequency of Candida mycoprofiles for
our chemotherapy cohort is likely due to factors associated with aging and with acquiring
cancer62,63. Compounding the predispositions affiliated with cancer and age is the tendency for
Candida sp., specifically C. albicans, to become pathogenic as a result of lowered immunity68. In
mouse models, C. albicans colonization, combined with gastrointestinal mucosal damage and
neutropenia resulted in dissemination of fungi and 100% mortality69. This is particularly
noteworthy for chemotherapy patients who often undergo mucosal damage and explains the
occurrence of Candida infections in individuals with Candida mycoprofiles in this study. C.
albicans commensals are not harmful, but have evolved the ability to become pathogenic when
appropriate conditions are met. In the GI tract for example, C. albicans colonize
heterogeneously with a mixture of cells expressing high and low levels levels of transcription
factor Efg1p, where absence of Efg1p causes hyper-colonization of the GI tract, but higher
susceptibility to the host immune system77. When the immune system is healthy, the balance of
Efg1p expressing cells tends to be toward higher expression of Efg1p, while in an immune
compromised state, the selective pressure is placed on cells expressing low levels of Efgp1.
With host immune defenses lowered, increased susceptibility of low-expressing Efg1p1 cells is
not able to trigger a sufficient immune response, and virulent variants are able to quickly
populate the niche5.
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Although it is debatable whether use of antifungals will alleviate symptoms of oral mucositis,
they have been shown to reduce mucositis-induced lesion sizes in one-third of individuals
displaying oral candidiasis61. It is especially important in a diagnostic setting to identify the
species causing infection. For instance, a common treatment for Candida infections is the
antifungal, Fluconazole. However, species of C. glabrata and C. krusei (Pichia kudriavzevii), two
of the most prominent causes of non-albicans candidiasis, are resistant to this drug due to
effective efflux pumps and an altered cytochrome P450, respectively78,79. Alternative treatments
that are effective against these species must be administered.
Here we have predominantly characterized the oral mycobiome at the genus level, but it may
not yet be sufficient for clinical use as anti-fungals are less broad and more specific to pathways
in certain species. As part of the study (data not shown), we have used reference sequences
from GenBank to assay the value of ITS1 sequences as a unique identifier for species within a
given genus. For the two most prevalent community genera in this study, Candida and
Malassezia, the ITS1 sequence resolves all of the species reported. In other genera, however,
species cannot be resolved by ITS1. For example, three Cladosporium species that were
assigned in our dataset were identical in the ITS1 region: cladosporioides (3 reference database
sequences used), tenuissimum (3 references) and cubutense (1 reference). Although
automated pipelines can, and often do report results at a lower taxonomic rank, it is important to
realize that the phylogenetic power of resolution may well be at a higher taxonomic level, so that
assumptions aren’t made about the species in question.

7.5

Conclusions

This work bridges the gap in fungal metagenomic studies by providing a roadmap to handling
the challenges of fungi from bench side to analysis and offers recommendations for
unpredictable samples and minimum sequencing efforts, while implementing current guidelines
for resolving genera and unclassified sequences30,59.With an improved pipeline and careful
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measures implemented to enhance the reliability of sequence classifications with empirically
determined parameters, such as our custom e-value threshold, we have characterized the core
oral mycobiome using results from deep sequencing of ITS1 amplicons and discovered a novel
oral genus, Malassezia.
We are also the first to attempt a metagenomic study of chemotherapy patients, which allowed
us to use our pipeline to characterize the frequency and presence of oral mycoprofiles. We
discovered that there is a vast difference in instances of Candida mycoprofiles for cancer
patients vs. healthy individuals and that patients with these profiles are highly susceptible to
infections. With the implications of Candida as opportunistic pathogens5, this is particularly
important for implementing prophylactic measures that may not only keep Candida at bay, but
also reduce the severity of oral mucositis61.
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Total Sequences
% of Sequences At Each
Step
% of Total Sequences
Lost
# Sequences Classified
by FMP
Max Length
Average Length
Min Length
Max E-value
Median E-value
Min E-value
Number Genera
Represented
(uncollapsed)
Top 10 taxa and Counts
1
2
3
4
5
6
7
8
9
10

Experimental Samples

4.7%
40044
535
70.3
46
0.076
1.00E-06
0

126
Fungi
Leptosphaeria
Eurotium
Physciella
Gongronella
Aspergillus
Suillus
Ascomycota
Athelia
Menegazzia

N/A
853178
816
240.4
40
9.8
1.00E-131
0

607
Malassezia
Epicoccum
Mortierella
Ascomycota
Cyberlindnera
Cortinarius
Fungi
Fusarium
Calostoma
Sydowia

233862
119656
66009
39878
39574
38799
37092
36510
27770
25081

4.7%

853653
100.0%

Raw
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29493
5338
1267
825
339
271
240
196
193
135

STEP 1- Dimer
Removal
Dimers
40046

Acaulospora
Glomus
Sydowia
Orpinomyces
Eurotium
Cladosporium
Glomeraceae
Tulasnellaceae
Stenocarpella
Alternaria

103

1338
578
465.2
72
9.1
0.003
2.00E-33

0.2%

0.2%

206
190
173
154
57
56
49
34
29
24

STEP 2- DeconSeq
Contamination
1352

Mortierella
Cortinarius
Calostoma
Sydowia
Orpinomyces
Malassezia
Cladosporium
Alternaria
Fungi
Epicoccum

514

246476
816
86.7
40
9.8
2.0E-04
0

28.9%

30.4%

65817
38418
27738
24872
13241
11812
10512
6449
5511
4550

STEP 3- QIIME
split_libraries.py
QIIME Fail
246905

Appendix 1. Statistics for ITS1 sequences from saliva removed during bioinformatics pipeline of
6 deeply sequenced healthy subjects

STEP 4- Length Filter
Less than 100 bp
7907
1.4%
0.9%
6836
99
92.1
4
8.1
7.5
2.00E-13
109
Cetrelia
Neopaxillus
Saccharomyces
Lecanora
Discoxylaria
Volvariella
Phialophora
Tuber
Bulbothrix
Lactarius

6063
220
104
47
39
31
23
23
15
14

STEP 5- E-value Filter
Unclassifiable
E-values > E-42
17716
66234
3.2%
11.9%
2.1%
7.8%
N/A
66234
541
600
223.3
286.2
100
100
N/A
10
N/A
9.00E-21
N/A
2.00E-42
N/A
596
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Lysurus
Saccharomyces
Periconia
Fungi
Ascomycota
Microstroma
Cryptococcus
Mutinus
Hygrophorus
Podosphaera

99

55362
1766
1643
348
325
263
229
188
164
155

Appendix 2. Individual subject demographics for arms 1-3
Key
Collection Date- Date saliva was collected
Sample ID EntryAge- Age in years
Gen- Gender: M= male, F= female
Eth- Ethnicity: 0= Hispanic, 1= Non-Hispanic
Race: 1= American Indian, 2= Asian, 3= Black, 4= Other/ Pacific Islander, 5= White
OU= OMAS Ulcers
OE= OMAS Erythemas
OT= OU+OE
COC= Candidiasis
Who= WHO Scale
Highlighted samples met requirements for sequencing efforts at all four time points

Collection Date

Sample ID Entry

1/20/2011 711-1-001-1-SA

Age Gen Eth Race OU OE OT COC Who
52

2/3/2011 711-1-001-4-SA
1/26/2011 711-1-002-1-SA

56

2/9/2011 711-1-002-4-SA
2/15/2011 711-1-003-1-SA

44

3/1/2011 711-1-003-4-SA
2/16/2011 711-1-004-1-SA

25

3/2/2011 711-1-004-4-SA
2/17/2011 711-1-005-1-SA

61

3/3/2011 711-1-005-4-SA
2/23/2011 711-1-006-1-SA

34

3/9/2011 711-1-006-4-SA
4/12/2011 711-1-007-1-SA

46

4/26/2011 711-1-007-4-SA
7/13/2011 711-1-008-1-SA

34

7/26/2011 711-1-008-4-SA
7/14/2011 711-1-009-1-SA

31

7/28/2011 711-1-009-4-SA
9/21/2011 711-1-010-1-SA

72

10/5/2011 711-1-010-4-SA

100

2/22/2012 711-1-011-1-SA

77

3/7/2012 711-1-011-4-SA
2/23/2012 711-1-012-1-SA

61

3/8/2012 711-1-012-4-SA
2/23/2012 711-1-013-1-SA

49

3/6/2012 711-1-013-4-SA
5/8/2012 711-1-014-1-SA

51

5/22/2012 711-1-014-4-SA
6/19/2012 711-1-016-1-SA

62

7/3/2012 711-1-016-4-SA
7/11/2012 711-1-017-1-SA

26

7/25/2012 711-1-017-4-SA
8/30/2012 711-1-018-1-SA

49

9/13/2012 711-1-018-4-SA
7/18/2012 711-1-019-1-SA

40

7/18/2012 711-1-019-4-SA
7/19/2012 711-1-020-1-SA

37

8/2/2012 711-1-020-4-SA
9/13/2012 711-1-021-1-SA

53

9/27/2012 711-1-021-4-SA
9/13/2012 711-1-022-1-SA

58

9/27/2012 711-1-022-4-SA
10/2/2012 711-1-023-1-SA

52

10/16/2012 711-1-023-4-SA
10/4/2012 711-1-024-1-SA

51

10/18/2012 711-1-024-4-SA
10/3/2012 711-1-025-1-SA

23

10/17/2012 711-1-025-4-SA
10/3/2012 711-1-026-1-SA

45

10/17/2012 711-1-026-4-SA
10/9/2012 711-1-027-1-SA

26

10/23/2012 711-1-027-4-SA
10/10/2012 711-1-028-1-SA

47

10/24/2012 711-1-028-4-SA
10/11/2012 711-1-029-1-SA

65

10/25/2012 711-1-029-4-SA
10/10/2012 711-1-030-1-SA

38

10/25/2012 711-1-030-4-SA
1/25/2011 711-2-001-1-SA

0

0

0

0

0

1/27/2011 711-2-001-2-SA

45

1

0

0

0

0

0

0

2/1/2011 711-2-001-3-SA

2

1

3

0

2

101

5

2/10/2011 711-2-001-4-SA

0

0

0

0

0

0

0

0

0

0

2/11/2011 711-2-002-2-SA

3

8 11

0

2

2/17/2011 711-2-002-3-SA

7

6 13

0

2

2/21/2011 711-2-002-4-SA

3

6

9

0

2

0

0

0

0

0

2/7/2011 711-2-002-1-SA

4/1/2011 711-2-003-1-SA

49

68

1

1

0

0

5

5

4/4/2011 711-2-003-2-SA

0

1

1

0

1

4/12/2011 711-2-003-3-SA

5

5 10

0

2

4/15/2011 711-2-003-4-SA

1

1

2

0

2

0

0

0

0

0

4/4/2011 711-2-004-2-SA

0

0

0

0

0

4/11/2011 711-2-004-3-SA

0

2

2

0

1

4/15/2011 711-2-004-4-SA

0

0

0

0

0

0

0

0

0

0

5/9/2011 711-2-005-2-SA

0

0

0

1

0

5/16/2011 711-2-005-3-SA

7

7 14

0

2

5/19/2011 711-2-005-4-SA

3

4

7

0

2

0

0

0

0

0

8/22/2011 711-2-006-2-SA

0

0

0

0

0

8/29/2011 711-2-006-3-SA

2

6

8

0

2

9/1/2011 711-2-006-4-SA

4

3

7

0

2

0

0

0

0

0

4/1/2011 711-2-004-1-SA

5/6/2011 711-2-005-1-SA

8/18/2011 711-2-006-1-SA

10/3/2011 711-2-007-1-SA

77

51

54

56

1

1

1

1

0

0

0

0

5

5

5

5

10/5/2011 711-2-007-2-SA

0

0

0

0

0

10/14/2011 711-2-007-3-SA

6

5 11

1

2

10/17/2011 711-2-007-4-SA

5

5 10

0

2

0

0

0

0

0

10/12/2011 711-2-008-2-SA

0

0

0

0

0

10/20/2011 711-2-008-3-SA

0

0

0

0

0

10/24/2011 711-2-008-4-SA

0

0

0

0

0

0

0

0

0

0

10/13/2011 711-2-009-2-SA

0

0

0

0

0

10/20/2011 711-2-009-3-SA

1

3

4

0

2

10/24/2011 711-2-009-4-SA

0

2

2

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1/20/2012 711-2-011-2-SA

0

0

0

0

0

1/26/2012 711-2-011-3-SA

8

7 15

1

2

0

0

0

0

0

0

0

0

0

0

0

1

1

0

0

10/11/2011 711-2-008-1-SA

10/11/2011 711-2-009-1-SA

10/12/2011 711-2-010-1-SA

32

48

50

2

2

1

0

0

0

5

5

5

10/14/2011 711-2-010-2-SA
1/17/2012 711-2-011-1-SA

80

1

0

5

2/2/2012 711-2-011-4-SA
1/19/2012 711-2-012-1-SA

53

2

0

1/23/2012 711-2-012-2-SA

102

5

1/30/2012 711-2-012-3-SA

0

0

0

0

0

2/2/2012 711-2-012-4-SA

0

0

0

0

0

0

0

0

0

0

2/8/2012 711-2-013-2-SA

0

0

0

0

0

2/16/2012 711-2-013-3-SA

0

0

0

0

0

2/21/2012 711-2-013-4-SA

0

0

0

0

0

2/6/2012 711-2-013-1-SA

2/27/2012 711-2-014-1-SA

58

0

0

0

0

0

0

0

0

0

3/8/2012 711-2-014-3-SA

0

0

0

0

0

3/13/2012 711-2-014-4-SA

0

0

0

0

0

0

0

0

0

0

3/5/2012 711-2-015-2-SA

0

0

0

0

0

3/9/2012 711-2-015-3-SA

2

9 11

0

2

3/15/2012 711-2-015-4-SA

3

5

8

0

2

0

0

0

0

0

3/19/2012 711-2-016-2-SA

0

0

0

0

0

3/27/2012 711-2-016-3-SA

0

0

0

0

0

3/30/2012 711-2-016-4-SA

0

0

0

0

0

0

0

0

0

0

4/2/2012 711-2-017-2-SA

0

2

2

0

1

4/5/2012 711-2-017-3-SA

3

2

5

0

2

4/12/2012 711-2-017-4-SA

0

1

1

0

0

3/16/2012 711-2-016-1-SA

3/28/2012 711-2-017-1-SA

3/30/2012 711-2-018-1-SA

91

54

2

1

0

0

5

5

0

0

0

0

1

6

7

0

2

4/9/2012 711-2-018-3-SA

3

4

7

0

2

4/12/2012 711-2-018-4-SA

1

1

2

0

2

0

0

0

0

0

5/17/2012 711-2-019-2-SA

0

0

0

0

0

5/23/2012 711-2-019-3-SA

0

2

2

0

1

6/1/2012 711-2-019-4-SA

0

0

0

0

0

0

0

0

0

0

7/5/2012 711-2-020-2-SA

0

0

0

1

0

7/12/2012 711-2-020-3-SA

1

2

3

1

2

7/18/2012 711-2-020-4-SA

1

9 10

1

2

0

0

0

0

0

7/13/2012 711-2-021-2-SA

2

2

4

0

2

7/18/2012 711-2-021-3-SA

5

6 11

0

2

7/23/2012 711-2-021-4-SA

0

6

6

0

1

7/3/2012 711-2-020-1-SA

7/9/2012 711-2-021-1-SA

9/26/2012 711-2-022-1-SA

50

60

67

2

1

2

1

0

5

0

66

1

0

5

4/2/2012 711-2-018-2-SA

5/16/2012 711-2-019-1-SA

63

1

0

5

0

55

2

1

2/28/2012 711-2-014-2-SA

3/2/2012 711-2-015-1-SA

32

2

0

0

0

0

5

3

5

5

0

0

0

0

0

10/2/2012 711-2-022-2-SA

0

0

0

0

0

10/4/2012 711-2-022-3-SA

0

2

2

0

1

103

3

10/10/2012 711-2-022-4-SA

1

2

3

0

0

0

0

0

0

0

11/12/2012 711-2-025-2-SA

0

0

0

0

0

11/14/2012 711-2-025-3-SA

1

2

3

0

2

11/21/2012 711-2-025-4-SA

0

0

0

0

0

0

0

0

0

0

11/16/2012 711-2-026-2-SA

0

0

0

0

0

11/26/2012 711-2-026-3-SA

2

3

5

0

0

11/29/2012 711-2-026-4-SA

0

0

0

0

0

0

0

0

0

0

12/13/2012 711-2-027-2-SA

0

0

0

0

0

12/20/2012 711-2-027-3-SA

6

6 12

0

2

12/27/2012 711-2-027-4-SA

1

1

2

0

2

0

0

0

0

0

2/28/2013 711-2-028-2-SA

0

2

2

0

0

3/7/2013 711-2-028-3-SA

0

0

0

0

0

3/13/2013 711-2-028-4-SA

0

0

0

0

0

0

0

0

0

0

3/15/2013 711-2-029-2-SA

1

2

3

1

2

3/21/2013 711-2-029-3-SA

0

0

0

0

0

3/27/2013 711-2-029-4-SA

0

0

0

0

0

0

0

0

0

0

4/23/2013 711-2-030-2-SA

0

0

0

0

0

5/3/2013 711-2-030-4-SA

0

0

0

0

0

0

0

0

0

0

5/16/2013 711-2-031-2-SA

0

1

1

0

0

5/21/2013 711-2-031-3-SA

3

7 10

0

2

5/24/2013 711-2-031-4-SA

2

2

4

0

2

0

0

0

0

0

7/18/2013 711-2-032-2-SA

0

1

1

0

0

7/23/2013 711-2-032-3-SA

1

1

2

0

2

7/29/2013 711-2-032-4-SA

2

3

5

0

2

0

0

0

0

0

8/7/2013 711-2-035-2-SA

0

1

1

0

0

8/12/2013 711-2-035-3-SA

0

0

0

0

0

8/19/2013 711-2-035-4-SA

0

0

0

0

0

0

0

0

0

0

8/8/2012 711-3-001-2-SA

0

0

0

1

0

8/16/2012 711-3-001-3-SA

0

5

5

1

1

8/22/2012 711-3-001-4-SA

0

0

0

1

0

0

0

0

0

0

11/7/2012 711-2-025-1-SA

11/14/2012 711-2-026-1-SA

12/12/2012 711-2-027-1-SA

2/25/2013 711-2-028-1-SA

3/13/2013 711-2-029-1-SA

4/19/2013 711-2-030-1-SA

5/13/2013 711-2-031-1-SA

7/16/2013 711-2-032-1-SA

8/5/2013 711-2-035-1-SA

7/24/2012 711-3-001-1-SA

8/6/2012 711-3-002-1-SA

80

35

63

65

63

53

62

82

52

50

60

1

2

1

2

1

1

1

1

1

1

2

0

0

0

0

0

0

0

0

0

0

0

104

3

5

5

5
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